<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antibiotic treatment for Clostridium difficile‐associated diarrhoea in adults - Nelson, RL - 2017 | Cochrane Library</title> <meta content="Antibiotic treatment for Clostridium difficile‐associated diarrhoea in adults - Nelson, RL - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004610.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antibiotic treatment for Clostridium difficile‐associated diarrhoea in adults - Nelson, RL - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004610.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004610.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Antibiotic treatment for &lt;i&gt;Clostridium difficile&lt;/i&gt;‐associated diarrhoea in adults" name="citation_title"/> <meta content="Richard L Nelson" name="citation_author"/> <meta content="University of Illinois School of Public Health" name="citation_author_institution"/> <meta content="altohorn@live.com" name="citation_author_email"/> <meta content="Katie J Suda" name="citation_author"/> <meta content="University of Illinois at Chicago" name="citation_author_institution"/> <meta content="Charlesnika T Evans" name="citation_author"/> <meta content="Northwestern University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD004610.pub5" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/03/03" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004610.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004610.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004610.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Clostridioides difficile; Aminoglycosides [therapeutic use]; Anti‐Bacterial Agents [adverse effects, *therapeutic use]; Bacitracin [therapeutic use]; Diarrhea [chemically induced, *drug therapy, microbiology]; Enterocolitis, Pseudomembranous [complications, *drug therapy]; Fidaxomicin; Metronidazole [therapeutic use]; Randomized Controlled Trials as Topic; Teicoplanin [therapeutic use]; Treatment Outcome; Vancomycin [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004610.pub5&amp;doi=10.1002/14651858.CD004610.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="na56WA6j";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004610\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004610\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004610\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004610\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","pt","fr","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004610.pub5",title:"Antibiotic treatment for   \u003ci\u003eClostridium difficile\u003c/i\u003e\\u2010associated diarrhoea in adults",firstPublishedDate:"Mar 3, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=na56WA6j&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004610.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004610.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004610.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004610.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004610.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004610.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004610.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004610.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004610.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004610.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>12518 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004610.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/full#CD004610-abs-0006"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/full#CD004610-sec-0078"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/full#CD004610-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/full#CD004610-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/full#CD004610-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/full#CD004610-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/full#CD004610-sec-0065"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/full#CD004610-sec-0072"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/appendices#CD004610-sec-0083"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/table_n/CD004610StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/table_n/CD004610StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antibiotic treatment for <i>Clostridium difficile</i>‐associated diarrhoea in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/information#CD004610-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Richard L Nelson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/information#CD004610-cr-0003">Katie J Suda</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004610.pub5/information#CD004610-cr-0004">Charlesnika T Evans</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/information/en#CD004610-sec-0089">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 03 March 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004610.pub5">https://doi.org/10.1002/14651858.CD004610.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004610-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004610-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004610-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004610-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004610-abs-0004">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD004610-abs-0003">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004610-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004610-abs-0001" lang="en"> <section id="CD004610-sec-0001"> <h3 class="title" id="CD004610-sec-0001">Background</h3> <p><i>Clostridium difficile</i> (<i>C. difficile</i>) is recognized as a frequent cause of antibiotic‐associated diarrhoea and colitis. This review is an update of a previously published Cochrane review. </p> </section> <section id="CD004610-sec-0002"> <h3 class="title" id="CD004610-sec-0002">Objectives</h3> <p>The aim of this review is to investigate the efficacy and safety of antibiotic therapy for <i>C. difficile‐</i> associated diarrhoea (CDAD), or <i>C. difficile</i> infection (CDI), being synonymous terms. </p> </section> <section id="CD004610-sec-0003"> <h3 class="title" id="CD004610-sec-0003">Search methods</h3> <p>We searched MEDLINE, EMBASE, CENTRAL and the Cochrane IBD Group Specialized Trials Register from inception to 26 January 2017. We also searched clinicaltrials.gov and clinicaltrialsregister.eu for ongoing trials. </p> </section> <section id="CD004610-sec-0004"> <h3 class="title" id="CD004610-sec-0004">Selection criteria</h3> <p>Only randomised controlled trials assessing antibiotic treatment for CDI were included in the review. </p> </section> <section id="CD004610-sec-0005"> <h3 class="title" id="CD004610-sec-0005">Data collection and analysis</h3> <p>Three authors independently assessed abstracts and full text articles for inclusion and extracted data. The risk of bias was independently rated by two authors. For dichotomous outcomes, we calculated the risk ratio (RR) and corresponding 95% confidence interval (95% CI). We pooled data using a fixed‐effect model, except where significant heterogeneity was detected, at which time a random‐effects model was used. The following outcomes were sought: sustained symptomatic cure (defined as initial symptomatic response and no recurrence of CDI), sustained bacteriologic cure, adverse reactions to the intervention, death and cost. </p> </section> <section id="CD004610-sec-0006"> <h3 class="title" id="CD004610-sec-0006">Main results</h3> <p>Twenty‐two studies (3215 participants) were included. The majority of studies enrolled patients with mild to moderate CDI who could tolerate oral antibiotics. Sixteen of the included studies excluded patients with severe CDI and few patients with severe CDI were included in the other six studies. Twelve different antibiotics were investigated: vancomycin, metronidazole, fusidic acid, nitazoxanide, teicoplanin, rifampin, rifaximin, bacitracin, cadazolid, LFF517, surotomycin and fidaxomicin. Most of the studies were active comparator studies comparing vancomycin with other antibiotics. One small study compared vancomycin to placebo. There were no other studies that compared antibiotic treatment to a placebo or a 'no treatment' control group. The risk of bias was rated as high for 17 of 22 included studies. Vancomycin was found to be more effective than metronidazole for achieving symptomatic cure. Seventy‐two per cent (318/444) of metronidazole patients achieved symptomatic cure compared to 79% (339/428) of vancomycin patients (RR 0.90, 95% CI 0.84 to 0.97; moderate quality evidence). Fidaxomicin was found to be more effective than vancomycin for achieving symptomatic cure. Seventy‐one per cent (407/572) of fidaxomicin patients achieved symptomatic cure compared to 61% (361/592) of vancomycin patients (RR 1.17, 95% CI 1.04 to 1.31; moderate quality evidence). Teicoplanin may be more effective than vancomycin for achieving a symptomatic cure. Eightly‐seven per cent (48/55) of teicoplanin patients achieved symptomatic cure compared to 73% (40/55) of vancomycin patients (RR 1.21, 95% CI 1.00 to 1.46; very low quality evidence). For other comparisons including the one placebo‐controlled study the quality of evidence was low or very low due to imprecision and in many cases high risk of bias because of attrition and lack of blinding. One hundred and forty deaths were reported in the studies, all of which were attributed by study authors to the co‐morbidities of the participants that lead to acquiring CDI. Although many other adverse events were reported during therapy, these were attributed to the participants' co‐morbidities. The only adverse events directly attributed to study medication were rare nausea and transient elevation of liver enzymes. Recent cost data (July 2016) for a 10 day course of treatment shows that metronidazole 500 mg is the least expensive antibiotic with a cost of USD 13 (Health Warehouse). Vancomycin 125 mg costs USD 1779 (Walgreens for 56 tablets) compared to fidaxomicin 200 mg at USD 3453.83 or more (Optimer Pharmaceuticals) and teicoplanin at approximately USD 83.67 (GBP 71.40, British National Formulary). </p> </section> <section id="CD004610-sec-0007"> <h3 class="title" id="CD004610-sec-0007">Authors' conclusions</h3> <p>No firm conclusions can be drawn regarding the efficacy of antibiotic treatment in severe CDI as most studies excluded patients with severe disease. The lack of any 'no treatment' control studies does not allow for any conclusions regarding the need for antibiotic treatment in patients with mild CDI beyond withdrawal of the initiating antibiotic. Nonetheless, moderate quality evidence suggests that vancomycin is superior to metronidazole and fidaxomicin is superior to vancomycin. The differences in effectiveness between these antibiotics were not too large and the advantage of metronidazole is its far lower cost compared to the other two antibiotics. The quality of evidence for teicoplanin is very low. Adequately powered studies are needed to determine if teicoplanin performs as well as the other antibiotics. A trial comparing the two cheapest antibiotics, metronidazole and teicoplanin, would be of interest. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004610-abs-0006" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004610-abs-0006">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004610-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004610-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004610-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004610-abs-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD004610-abs-0010">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD004610-abs-0009">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004610-abs-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD004610-abs-0008">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004610-abs-0006" lang="en"> <h3>Antibiotic therapy for Clostridium difficile‐associated diarrhoea in adults</h3> <p>Background</p> <p><i>Clostridium difficile</i> (<i>C. difficile</i> ) is a bacterium that can live harmlessly in the colon, but when an individual takes an antibiotic for another condition, the <i>C. difficile</i> can grow and replace most of the normal bacterial flora that live in the colon. This overgrowth causes <i>C. difficile</i> ‐associated diarrhoea (also known as <i>C. difficile</i> infection ‐ CDI). The symptoms of CDI include diarrhoea, fever and pain. CDI may be only mild but in many cases is very serious and, if untreated, can be fatal. There are many proposed treatments for CDI, but the most common are withdrawing the antibiotic that caused the CDI and prescribing an antibiotic that kills the bacterium. Many antibiotics have been tested in clinical trials for effectiveness and this review studies the comparisons of these antibiotics. This review is an update of a previously published Cochrane review. </p> <p>Methods</p> <p>We searched the medical literature up to 26 January 2017. All randomised trials that compare two different antibiotics, or variations in dosing of a single antibiotic for treatment of CDI were included. Trials comparing antibiotic to placebo (e.g. a sugar pill) or no treatment were sought but, save for one poor quality placebo‐controlled trial, none were found. Trials that compared antibiotics to a non‐antibiotic treatment were not included. </p> <p>Results</p> <p>Twenty‐two studies (total 3215 participants) were included. The majority of studies enrolled participants with mild to moderate CDI who could tolerate oral antibiotics. Sixteen of the included studies excluded participants with severe CDI and few participants with severe CDI were included in the other studies. Twelve different antibiotics were assessed. Most of the studies compared vancomycin or metronidazole with other antibiotics. One small study compared vancomycin to placebo (e.g. sugar pill). There were no other studies that compared antibiotic treatment to a placebo or a no treatment control group. Seventeen of the 22 included studies had quality issues. In four studies, vancomycin was found to be superior to metronidazole for achieving sustained symptomatic cure (defined as resolution of diarrhoea and no recurrence of CDI). We rated the quality of the evidence supporting this finding as moderate. A new antibiotic, fidaxomicin, was, in two large studies, found to be superior to vancomycin. The quality of the evidence supporting this finding was moderate. It should be noted that the differences in effectiveness between these antibiotics were not too great and that metronidazole is far less expensive than either vancomycin and fidaxomicin. A pooled analysis of two small studies suggests that teicoplanin may be more effective than vancomycin for achieving symptomatic cure. The quality of the evidence supporting this finding was very low. The quality of the evidence for the other seven antibiotics in this review was very poor because the studies were very small, and many patients dropped out of these studies before completion. One hundred and forty deaths were reported in the studies, all of which were attributed to participants preexisting health problems. The only side effects attributed to antibiotics were rare nausea and temporary elevation of liver enzymes. Recent cost data (July 2016) for a 10 day course of treatment shows that metronidazole 500 mg is the least expensive antibiotic with a cost of USD 13. Vancomycin 125 mg costs USD 1779 compared to fidaxomicin 200 mg at USD 3453.83 or more and teicoplanin at approximately USD 83.67. </p> <p>Conclusion</p> <p>No firm conclusions can be drawn regarding the effectiveness of antibiotic treatment in severe CDI as most studies excluded these patients. The lack of any 'no treatment' control studies does not allow for any conclusions regarding the need for antibiotic treatment in patients with mild CDI beyond withdrawal of the antibiotic that caused CDI. Nonetheless, moderate quality evidence suggests that vancomycin is superior to metronidazole and fidaxomicin is superior to vancomycin. The differences in effectiveness between these antibiotics were not too large and the advantage of metronidazole is its far lower cost compared to the other antibiotics. The quality of evidence for teicoplanin is very low. Larger studies are needed to determine if teicoplanin performs as well as the other antibiotics. A trial comparing the two cheapest antibiotics, metronidazole and teicoplanin would be of interest. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004610-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004610-sec-0078"></div> <h3 class="title" id="CD004610-sec-0079">Implications for practice</h3> <section id="CD004610-sec-0079"> <p>Although antibiotic therapy for CDI is universally prescribed, the evidence specifically for any antibiotic therapy for CDI is not supported by randomised trials, as the only placebo‐controlled study is inadequate. The same can be said for many surgical treatments of this potentially fatal disease, and one cannot envision those RCTs ever being done. No firm conclusions can be drawn regarding the efficacy of antibiotic treatment in severe CDI as most studies excluded patients with severe disease. But for an asymptomatic carrier of <i>C. difficile</i> or one with mild symptoms, the indication for treatment is more doubtful. The lack of any 'no treatment' control studies does not allow for any conclusions regarding the need for antibiotic treatment in patients with mild CDI beyond withdrawal of the initiating antibiotic. This review also cannot define the efficacy or timing of cessation of the initial, offending antibiotic, because none of the included studies applied a strict or consistent protocol in regard to its continuation. As a corollary, this review cannot establish the proper amount of time between cessation of the initial antibiotic and beginning antibiotic therapy for CDI, to see if the offending antibiotic might be causing diarrhoea by a mechanism other than <i>C. difficile</i> overgrowth, as none of the above studies addressed this research question. When an antibiotic for CDI is chosen, moderate quality evidence suggests that vancomycin is superior to metronidazole and fidaxomicin is superior to vancomycin. The differences in effectiveness between these antibiotics were not too large and the advantage of metronidazole is its far lower cost compared to the vancomycin and fidaxomicin. Current guidelines generally recommend metronidazole or vancomycin depending on the clinical situation. Teicoplanin may be a more effective alternative to vancomycin but the quality of the evidence is very low. </p> </section> <h3 class="title" id="CD004610-sec-0080">Implications for research</h3> <section id="CD004610-sec-0080"> <p>Given the uncertainty involved in antibiotic therapy for CDI, adequately powered, placebo‐controlled, randomised trials that assess (1) cessation of the initial antibiotic and (2) timing and duration of CDI therapy are recommended. This is really important since many antibiotics can cause diarrhoea separate from CDI and by a different mechanism. In such cases, withdrawal of that antibiotic cures the diarrhoea. All included studies treated the antibiotic that gave rise to CDI in a haphazard way, in many cases treating doctors feeling that the primary disease needed ongoing treatment. The rigorousness of CDI diagnosis suffers in this situation. Vancomycin or metronidazole should be considered for these studies. Teicoplanin should be considered for further investigation because it may be superior to both of these antibiotics. A trial comparing the two cheapest antibiotics, metronidazole and teicoplanin, would be of interest. Such trials would require the randomisation of a large number of patients. These comparisons may help to determine which, if any, antibiotic is most suitable for treating CDI. There should be strict criteria for the diagnosis of CDI: prior exposure to antibiotics, persistent diarrhoea that does not respond to removal of the offending antibiotic and supportive therapy. The primary outcomes should be sustained symptomatic cure, defined as cessation of symptoms during the time of treatment and for 30 to 60 days after, and evidence of sustained bacteriologic cure, defined as symptomatic cure above. Secondary outcomes should include adverse events related to the intervention, surgery and death. If disease severity is to be a factor in antibiotic choice, severity should be assessed prior to randomisation. </p> <p>It would be useful to develop a universal system for grading the severity of CDI. The increasing severity of the disease also highlights the need to investigate antibiotic treatment in severely ill patients with CDI. Data for this group are currently lacking. Other issues that need to be addressed in future trials include: the treatment of recurrent symptoms, the use of intravenous compared to oral antibiotics, antibiotic resistance, synergistic antibiotic combinations and other types of interventions (e.g. the use resins combined with antibiotics, vaccines, or fecal repopulation). </p> <p>The most recent guidelines used a new assay that has increased sensitivity, with the implication from the CDC that this PCR test is now the gold standard. However the sensitivity of this method has resulted in the possible over diagnosis of CDI (<a href="./references#CD004610-bbs2-0050" title="BagdasarianN , RaoK , MalaniPN . Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA2015;313(4):398‐408. ">Bagdasarian 2015</a>), which may be in part be a result of the increasing incidence of CDI (<a href="./references#CD004610-bbs2-0076" title="LessaFC , MuY , BambergWM , BeldavsZG , DumyatiGK , DunnJR , et al. Burden of Clostridium difficile infection in the United States. New England Journal of Medicine2015;372(9):825‐34. ">Lessa 2015</a>). Despite the growing popularity of PCR, none of the included studies used PCR for the diagnosis of CDI. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004610-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004610-sec-0036"></div> <div class="table" id="CD004610-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Metronidazole versus vancomycin for Clostridium difficile‐associated diarrhoea in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Metronidazole versus Vancomycin for Clostridium difficile‐associated diarrhoea in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Clostridium difficile‐associated diarrhoea in adults<br/> <b>Settings:</b> <br/> <b>Intervention:</b> Metronidazole versus Vancomycin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Metronidazole versus Vancomycin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic cure with all exclusions treated as failures</b> <br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>792 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>713 per 1000</b> <br/> (665 to 768) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.9</b> <br/> (0.84 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>872<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bacteriologic cure</b> <br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>529 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>449 per 1000</b> <br/> (328 to 619) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b> <br/> (0.62 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cure (combined symptomatic and bacteriologic cure) ‐ mild disease</b> <br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>841 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>740 per 1000</b> <br/> (597 to 917) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> <br/> (0.71 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cure (combined symptomatic and bacteriologic cure) ‐ severe disease</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>711 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>526 per 1000</b> <br/> (369 to 739) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.74</b> <br/> (0.52 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk comes from control arm of meta‐analysis, based on included trials.<br/> <sup>2</sup> High risk of bias.<br/> <sup>3</sup> Serious imprecision.<br/> <sup>4</sup> Unclear risk of bias.<br/> <sup>5</sup> Unclear if stratification by severity was post hoc. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004610-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Teicoplanin versus vancomycin for Clostridium difficile‐associated diarrhoea in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Teicoplanin versus Vancomycin for Clostridium difficile‐associated diarrhoea in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Clostridium difficile‐associated diarrhoea in adults<br/> <b>Settings:</b> <br/> <b>Intervention:</b> Teicoplanin versus Vancomycin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Teicoplanin versus Vancomycin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic Cure</b> <br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>727 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>880 per 1000</b> <br/> (727 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21</b> <br/> (1 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bacteriologic Cure</b> <br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>452 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>822 per 1000</b> <br/> (537 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.82</b> <br/> (1.19 to 2.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk comes from control arm of meta‐analysis, based on included trials. <br/> <sup>2</sup> High risk of bias. Blinding not done in either study and other pathogens not excluded in Wenisch<br/> <sup>3</sup> Serious imprecision. Two very small studies<br/> <sup>4</sup> Serious imprecision. Just a single small study </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004610-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Fidaxomicin compared to vancomycin for Clostridium difficile‐associated diarrhoea in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fidaxomicin compared to Vancomycin for Clostridium difficile‐associated diarrhoea in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Clostridium difficile‐associated diarrhoea in adults<br/> <b>Settings:</b> <br/> <b>Intervention:</b> Fidaxomicin<br/> <b>Comparison:</b> Vancomycin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Vancomycin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Fidaxomicin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic Cure</b> <br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>610 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>713 per 1000</b> <br/> (652 to 774) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.17</b> <br/> (1.07 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1164<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk comes from control arm of meta‐analysis, based on included trials.<br/> <sup>2</sup> High risk of bias in both studies. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004610-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Bacitracin versus vancomycin for Clostridium difficile‐associated diarrhoea in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bacitracin versus Vancomycin for Clostridium difficile‐associated diarrhoea in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Clostridium difficile‐associated diarrhoea in adults<br/> <b>Settings:</b> <br/> <b>Intervention:</b> Bacitracin versus Vancomycin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Bacitracin versus Vancomycin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic Cure</b> <br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>462 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>268 per 1000</b> <br/> (157 to 457) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.58</b> <br/> (0.34 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk comes from control arm of meta‐analysis, based on included trials.<br/> <sup>2</sup> High risk of bias. Attrition and blinding issues in one trial.<br/> <sup>2</sup> Very serious imprecision. Two very small studies with few events. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004610-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004610-sec-0037"></div> <section id="CD004610-sec-0038"> <h3 class="title" id="CD004610-sec-0038">Description of the condition</h3> <p>The administration of antibiotics is known to be associated with the development of diarrhoea in patients. Erythromycin and the clavulanate in amoxicillin‐clavulanate cause diarrhoea by accelerating gastrointestinal motility (<a href="./references#CD004610-bbs2-0054" title="BartlettJG . Clinical practice. Antibiotic‐associated diarrhea. New England Journal of Medicine2002;346(5):334‐9. ">Bartlett 2002</a>). Still other antibiotics are thought to cause diarrhoea by reducing the number of fecal anaerobes, thereby decreasing carbohydrate digestion and absorption, leading to an osmotic diarrhoea (<a href="./references#CD004610-bbs2-0054" title="BartlettJG . Clinical practice. Antibiotic‐associated diarrhea. New England Journal of Medicine2002;346(5):334‐9. ">Bartlett 2002</a>). Nearly 15% of hospitalised patients receiving beta‐lactam antibiotics develop diarrhoea (<a href="./references#CD004610-bbs2-0080" title="McFarlandLV , SurawiczCM , GreenbergRN , ElmerGW , MoyerKA , MelcherSA , et al. Prevention of beta‐lactam‐associated diarrhea by Saccharomyces boulardii compared with placebo. American Journal of Gastroenterology1995;90(3):439‐48. ">McFarland 1995</a>). <i>Clostridium difficile</i> (<i>C. difficile)</i> infection of the colon (CDI) is another cause of antibiotic‐associated diarrhoea that is thought to be caused by a presumed overgrowth of native or newly acquired <i>C. difficile</i> (<a href="./references#CD004610-bbs2-0061" title="FeketyR , ShahAB . Diagnosis and treatment of Clostridium difficile colitis. JAMA1993;269(1):71‐5. ">Fekety 1993</a>). <i>C. difficile</i> is implicated in 20 to 30% of patients with antibiotic‐associated diarrhoea, in 50 to 70% of those with antibiotic‐associated colitis and in more than 90% of those with antibiotic‐associated pseudomembranous colitis (<a href="./references#CD004610-bbs2-0052" title="BartlettJG , TaylorNS , ChangT , DzinkJ . Clinical and laboratory observations in Clostridium difficile colitis. American Journal of Clinical Nutrition1980;33(11 Suppl):2521‐6. ">Bartlett 1980</a>; <a href="./references#CD004610-bbs2-0053" title="BartlettJG . Clostridium difficile: clinical considerations. Reviews of Infectious Diseases1990;12 Suppl 2:S243‐51. ">Bartlett 1990</a>; <a href="./references#CD004610-bbs2-0064" title="GeorgeWL , RolfeRD , FinegoldSM . Clostridium difficile and its cytotoxin in feces of patients with antimicrobial agent‐associated diarrhea and miscellaneous conditions. Journal of Clinical Microbiology1982;15(6):1049‐53. ">George 1982</a>; <a href="./references#CD004610-bbs2-0073" title="KellyCP , PothoulakisC , LaMontJT . Clostridium difficile colitis. New England Journal of Medicine1994;330(4):257‐62. ">Kelly 1994</a>). Approximately 5% of healthy adults asymptomatically carry low concentrations of <i>C. difficile</i> in their colon, and the growth of these bacteria has been shown <i>in vitro</i> to be held in check by normal gut flora (<a href="./references#CD004610-bbs2-0061" title="FeketyR , ShahAB . Diagnosis and treatment of Clostridium difficile colitis. JAMA1993;269(1):71‐5. ">Fekety 1993</a>). The exact mechanism by which <i>C. difficile</i> overgrowth occurs is still unclear, but it can occur with the administration of oral, parenteral or topical antibiotics (<a href="./references#CD004610-bbs2-0061" title="FeketyR , ShahAB . Diagnosis and treatment of Clostridium difficile colitis. JAMA1993;269(1):71‐5. ">Fekety 1993:</a><a href="./references#CD004610-bbs2-0092" title="ThomasC , StevensonM , RileyTV . Antibiotics and hospital‐acquired Clostridium difficile‐associated diarrhoea: a systematic review. Journal of Antimicrobial Chemotherapy2003;51(6):1339‐50. ">Thomas 2003</a>). </p> <p>It is important to explain the terms used in conjunction with <i>C. difficile</i> infection, as the studies analysed in this review involve various descriptions of <i>C. difficile</i> disease. <i>Clostridium difficile</i> ‐associated diarrhoea (CDAD) occurs in a patient with diarrhoea that has tested positive for <i>C. difficile</i> toxin or a positive stool culture for <i>C. difficile</i> . <i>C. difficile</i> colitis involves a stool test positive for the organism and signs of mucosal inflammation seen on endoscopy. Pseudomembranous colitis refers to the actual presence of pseudomembranes seen on endoscopy. CDI is a term used in an increasing number of publications but by no means to the exclusion of CDAD. Both terms connote a patient with symptomatic diarrhoea and laboratory evidence of <i>C. difficile</i> as the cause of that diarrhoea. Pseudomembranous colitis is meant to connote the same disease but is not quite synonymous, as many patients with antibiotic‐associated diarrhoea do not undergo the endoscopy and biopsy necessary for the diagnosis of colitis or the endoscopy and visualization of pseudomembranes. This systematic review will use the term CDI for all forms of symptomatic <i>C. difficile</i> infection for its analyses. This review is an update of a previously published Cochrane review (<a href="./references#CD004610-bbs2-0095" title="BrickerE , GargR , NelsonR , LozaA , NovakT , HansenJ . Antibiotic treatment for Clostridium difficile‐associated diarrhea in adults. Cochrane Database of Systematic Reviews2005, Issue 1. [DOI: 10.1002/14651858.CD004610.pub2] ">Bricker 2005</a>; <a href="./references#CD004610-bbs2-0096" title="NelsonR . Antibiotic treatment for Clostridium difficile‐associated diarrhea in adults. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD004610.pub3] ">Nelson 2007</a>; <a href="./references#CD004610-bbs2-0097" title="NelsonRL , KelseyP , LeemanH , MeardonN , PatelH , PaulK , et al. Antibiotic treatment for Clostridium difficile‐associated diarrhea in adults. Cochrane Database of Systematic Reviews2011, Issue 9. [DOI: 10.1002/14651858.CD004610.pub4] ">Nelson 2011</a>), and includes six new trials assessing three new antibiotics. </p> </section> <section id="CD004610-sec-0039"> <h3 class="title" id="CD004610-sec-0039">Description of the intervention</h3> <p>The standard treatment for primary infection caused by <i>C. difficile</i> is an antibiotic. This is usually done in conjunction with with the cessation of the antibiotic that caused the alteration of the gut flora in the first place (when feasible, considering the patient's clinical condition) with subsequent overgrowth of <i>Clostridium difficile</i>. </p> </section> <section id="CD004610-sec-0040"> <h3 class="title" id="CD004610-sec-0040">How the intervention might work</h3> <p>By treatment with an antibiotic that is specifically effective against <i>Clostridium difficile</i>, toxin production is reduced and repopulation of the gut with normal gut flora is possible. </p> </section> <section id="CD004610-sec-0041"> <h3 class="title" id="CD004610-sec-0041">Why it is important to do this review</h3> <p>During the early part of the 21st century, much higher mortality rates from CDI than previous reports were reported in Quebec (<a href="./references#CD004610-bbs2-0083" title="PepinJ , ValiquetteL , CossetteB . Mortality attributable to nosocomial Clostridium difficile‐associated disease during an epidemic caused by a hypervirulent strain in Quebec. Canadian Medical Association Journal2005;173(9):1037‐42. ">Pepin 2005</a>). This was related to the appearance of a new variant of <i>C. difficile</i>, which is capable of secreting much higher amounts of toxin A and B and is more resistant to standard antibiotic therapy (<a href="./references#CD004610-bbs2-0078" title="LouieTJ . How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?. Canadian Medical Association Journal2005;173(9):1049‐50. ">Louie 2005</a>). This new variant resulted in a higher incidence of CDI among hospitalised patients (<a href="./references#CD004610-bbs2-0079" title="McDonaldLC , KillgoreGE , ThompsonA , OwensRCJr , KazakovaSV , SambolSP , et al. An epidemic, toxin gene‐variant strain of Clostridium difficile . New England Journal of Medicine2005;353(23):2433‐41. ">McDonald 2005</a>), a greater need for urgent colectomy for toxic colitis and a high mortality rate (e.g. 37%; <a href="./references#CD004610-bbs2-0083" title="PepinJ , ValiquetteL , CossetteB . Mortality attributable to nosocomial Clostridium difficile‐associated disease during an epidemic caused by a hypervirulent strain in Quebec. Canadian Medical Association Journal2005;173(9):1037‐42. ">Pepin 2005</a>). This variant, ribotype 027, has spread from Quebec to the USA, and Europe (<a href="./references#CD004610-bbs2-0078" title="LouieTJ . How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?. Canadian Medical Association Journal2005;173(9):1049‐50. ">Louie 2005</a>; <a href="./references#CD004610-bbs2-0075" title='LaurenceJ . Deaths from "dirty hospital bug" double in five years. The Independant 26 May, 2006:11. '>Laurence 2006</a>). In the United States hospitalizations for CDI doubled between 2000 and 2010 and was expected to continue to increase in 2011 and 2012. CDI is the leading cause of gastrointestinal‐related death in the USA. CDI is estimated to have caused 14,000 deaths in the USA in 2007 and is the most common healthcare‐associated infection. The estimated cost of CDI is USD 4,800 million per year for acute care facilities alone in the USA (<a href="./references#CD004610-bbs2-0076" title="LessaFC , MuY , BambergWM , BeldavsZG , DumyatiGK , DunnJR , et al. Burden of Clostridium difficile infection in the United States. New England Journal of Medicine2015;372(9):825‐34. ">Lessa 2015</a>). Unlike the UK, where both incidence and mortality have declined in recent years (<a href="./references#CD004610-bbs2-0070" title="Health Protection Agency. Deaths involving Clostridium difficile or MRSA, Wales: 2015. www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsinvolvingclostridiumdifficilewales/2015 (accessed 26 January 2017). ">HPA 2016</a>), the Agency for Healthcare Research and Quality has shown a consistent increase in CDI from the turn of the century through 2015 (<a href="./references#CD004610-bbs2-0048" title="Minnesota Evidence‐based Practice Center. Early diagnosis, prevention and treatment of Clostridium difficile: Update. AHRQ Publication No. 16‐EHC012‐EFMarch, 2016; Vol. #172:1‐37. ">AHRQ 2016</a>; <a href="./references#CD004610-bbs2-0090" title="SteinerC , BarrettM , SunY . HCUP projections: Clostridium difficile hospitalizations. HCUP Projections Report2015;02:1‐12. ">Steiner 2015</a>). </p> <p>The emergence of this highly virulent bacterium adds urgency to the identification of effective therapy. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004610-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004610-sec-0042"></div> <p>The aim of this review was to investigate the efficacy and safety of antibiotic therapy for CDI, to identify the most effective antibiotic treatment for CDAD in adults and to determine the need for stopping the causative antibiotic during therapy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004610-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004610-sec-0043"></div> <section id="CD004610-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004610-sec-0045"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) assessing antibiotic treatment for CDI were considered for inclusion. </p> </section> <section id="CD004610-sec-0046"> <h4 class="title">Types of participants</h4> <p>The types of participants included:<br/> (I) patients with diarrhoea: various definitions exist usually describing the consistency of stool, number of bowel movements per day, duration of symptoms, and rarely stool volume;<br/> (ii) patients with <i>C. difficile</i> in stool identified by stool culture positive for <i>C. difficile</i> and or by stool positive for <i>C. difficile</i> cytotoxin;<br/> (iii) patients who had received prior antibiotic therapy for an infection other than <i>C. difficile;</i> and<br/> (iv) patients 18 years of age of older. </p> <p>Patients were excluded if they did not have diarrhoea or if there was no evidence of <i>C. difficile</i> infection. </p> </section> <section id="CD004610-sec-0047"> <h4 class="title">Types of interventions</h4> <p>Only studies involving antibiotic therapy for <i>C. difficile‐</i>associated diarrhoea were included. These studies may include comparisons among different antibiotics, between different timing or doses of the same antibiotic, or between antibiotic therapy and placebo. Studies were excluded if they compared antibiotic to non‐antibiotic therapy (such as resins, vaccines, probiotics or biologicals) or if, in conjunction with antibiotic treatment, the intervention being tested was of a non‐antibiotic such as those listed above. In addition interventions used for the prevention of CDI are not included in this review. </p> </section> <section id="CD004610-sec-0048"> <h4 class="title">Types of outcome measures</h4> <p>The following outcomes were sought:</p> <p>Sustained symptomatic cure: An initial resolution of the diarrhoea and no evidence of recurrence of diarrhoea due to CDI. </p> <p>Bacteriologic cure: Conversion from a stool positive for any CDI assay to negative and no recurrence of CDI. </p> <p>No specific minimum time limit was set for either of these determinations of recurrence.</p> <p>Death.</p> <p>Drug‐related adverse events (DRAE) of the antibiotic treatments.</p> <p>Cost of each of the major antibiotics.</p> </section> </section> <section id="CD004610-sec-0049"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004610-sec-0050"> <h4 class="title">Electronic searches</h4> <p>We searched MEDLINE, EMBASE , CENTRAL and the Cochrane IBD Group Specialized Register from inception to 26 January 2017. The search strategies are reported in <a href="./appendices#CD004610-sec-0084">Appendix 1</a>. Studies published only as abstracts were not explicitly excluded. </p> </section> <section id="CD004610-sec-0051"> <h4 class="title">Searching other resources</h4> <p>In addition, trials were sought in the Clinicaltrials.gov and Clinicaltrialsregister.eu registers using the search term '<i>Clostridium difficile</i>'. </p> </section> </section> <section id="CD004610-sec-0052"> <h3 class="title" id="CD004610-sec-0052">Data collection and analysis</h3> <section id="CD004610-sec-0053"> <h4 class="title">Selection of studies</h4> <p>At least two authors (three in this update) examined all the citations and abstracts derived from the electronic search strategy and independently selected trials to be included. Full reports of potentially relevant trials were retrieved to assess eligibility. Reviewers were not blind to the names of trials' authors, institutions or journals. Any disagreements about trial inclusion were resolved by group discussion. </p> </section> <section id="CD004610-sec-0054"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was performed independently by at least two authors (three in this update). Results were compared between reviewers and all studies were presented for group discussion. Where data may have been collected but not reported, further information was sought from the individual trial authors. When dropouts occurred and were not included in the analyses, and the randomisation group was known, these dropouts were treated as treatment failures in this meta‐analysis. </p> </section> <section id="CD004610-sec-0055"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the included studies using the Cochrane Collaboration tool for assessing risk of bias (<a href="./references#CD004610-bbs2-0067" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Criteria for quality assessment includes: </p> <p><b>(1) Selection bias:</b> <br/> We rated random sequence generation as 'low risk' if the investigators described a random component in the sequence generation process. We rated as 'high risk' if the investigators described a non‐random component in the sequence generation process. We rated as 'unclear risk' if insufficient information about the sequence generation process was provided. </p> <p><b>(2) Performance bias:</b> <br/> We rated allocation sequence concealment as 'low risk' if participants and investigators enrolling participants could not foresee treatment assignment. We rated as 'high risk' if participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias. We rated as 'unclear risk' if the method of concealment was not described or not described in sufficient detail to allow a definite judgement. </p> <p><b>(3) Detection bias:</b> <br/> We rated blinding of participants and personnel as 'low risk' if blinding of participants and personnel was ensured, and it was unlikely that the blinding could have been broken. We rated as 'high risk' if there was no blinding or incomplete blinding, and the outcome was likely to be influenced by a lack of blinding or blinding of participants was attempted, but it was likely that the blinding could have been broken, and the outcome was likely to be influenced by lack of blinding. We rated as 'unclear risk' if insufficient information was provided to allow a definite judgement.<br/> <br/> We rated binding of outcome assessment as 'low risk' if blinding of outcome assessors was ensured, and it was unlikely that the blinding could have been broken. However, due to the nature of the intervention, for several outcome items blinding of outcome assessors was not possible and may be a potential source of bias. We rated as 'high risk' if if there was no blinding of outcome assessors, and the outcome was likely to be influenced by a lack of blinding or blinding of outcome assessors was attempted, but it was likely that the blinding could have been broken, and the outcome was likely to be influenced by a lack of blinding. We rated as 'unclear risk' if insufficient information was provided to allow a definite judgement. </p> <p><b>(4) Attrition bias:</b> <br/> We rated incomplete outcome data as 'low risk' if there were no missing outcome data, or if there were fewer than 10% post‐randomisation dropouts or withdrawals. We rated as 'high risk' if the reason for missing outcome data was likely to be related to the true outcome. We rated as 'unclear risk' if there was insufficient reporting of attrition and exclusions to permit judgement. </p> <p>We rated selective reporting as 'low risk' if the study protocol was available and all of the pre‐specified primary and secondary outcomes that were of interest to the review were reported in the pre‐specified manor or the study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre‐specified. We rated as 'high risk' if the pre‐specified primary outcomes were not all reported, or one or more outcomes of interest for the review were reported incompletely so that the data could not be used for meta‐analysis, or the study report failed to include results for a key outcome that would be expected to have been reported for such a study. We rated as 'unclear risk' if insufficient information was provided to allow a definite judgement. </p> <p><b>(5) Selective Reporting</b> </p> <p>Selective reporting was focused in this review on whether recurrence data were collected and presented for each study. This is a necessary element in the determination of sustained clinical response. </p> <p><b>(6) Other bias</b> <br/> We rated other bias as 'low risk' if the study appears to be free of other sources of bias. We rated as 'high risk' if there was at least one other important risk of bias. We rated as 'unclear risk' if there may have been a risk of bias, but there was either insufficient information to assess whether an important risk of bias exists or insufficient rationale or evidence that an identified problem introduced bias. </p> </section> <section id="CD004610-sec-0056"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we calculated the risk ratio (RR) with corresponding 95% confidence interval (95% CI). </p> </section> <section id="CD004610-sec-0057"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual patient.</p> </section> <section id="CD004610-sec-0058"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study authors for missing data. Dropouts were considered to be treatment failures for the analyses. </p> </section> <section id="CD004610-sec-0059"> <h4 class="title">Assessment of heterogeneity</h4> <p>Clinical heterogeneity was assessed by examining the patient population, interventions and outcome definition and assessment. Methodological heterogeneity was assessed by looking at the components of the risk of bias assessment. Statistical heterogeneity was assessed by calculating the Chi<sup>2</sup> and I<sup>2</sup> statistics. We considered heterogeneity to be significant if the the P value for Chi<sup>2</sup> was &lt; 0.10 or I<sup>2</sup> was &gt; 60%. </p> </section> <section id="CD004610-sec-0060"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed selective reporting as described above. If any of the pooled analyses included 10 or more studies, we planned to assess potential publication bias by constructing a funnel plot. </p> </section> <section id="CD004610-sec-0061"> <h4 class="title">Data synthesis</h4> <p>Data were entered and analysed in Revman 5.3. For dichotomous outcomes we calculated the pooled RR and corresponding 95% CI. Due to the small number of studies in each analysis and the lack of statistical heterogeneity in those few analyses with more than one study, a fixed‐effect model was used for comparisons with more than one included study. When considerable clinical heterogeneity was encountered between comparisons, as in <a href="./references#CD004610-fig-0004" title="">Analysis 1.1</a>, both fixed‐effect and random‐effects models were calculated. </p> </section> <section id="CD004610-sec-0062"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>For this systematic review, we assessed specific antibiotics individually. No further subgroup analyses were planned. </p> </section> <section id="CD004610-sec-0063"> <h4 class="title">Sensitivity analysis</h4> <p>We planned for sensitivity analyses based on study quality. Howveer, given the poor overall quality of the studies in this systematic review no sensitivity analyses are reported in this update. </p> <section id="CD004610-sec-0064"> <h5 class="title">Summary of Findings</h5> <p>All included studies are RCTs. We used the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach to assess the overall quality of the evidence supporting the primary outcome and selected secondary outcomes (<a href="./references#CD004610-bbs2-0086" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, Available from www.cochrane‐handbook.org, 2011. ">Schünemann 2011</a>). The overall quality of evidence can be graded into four levels: </p> <p>1. High: Further research is very unlikely to change our confidence in the estimate of effect; </p> <p>2. Moderate: Further research is likely to have an impact on our confidence in the estimate of effect and may change the estimate; </p> <p>3. Low: Further research is very likely to have an important impact on our confidence on the estimate of effect and is likely to change the estimate; or </p> <p>4. Very low: Any estimate of effect is very uncertain.</p> <p>The overall quality of evidence can be downgraded by one (serious concern) or two levels (very serious concern) for the following reasons: risk of bias, inconsistency (e.g. unexplained heterogeneity, inconsistency of results), indirectness (e.g. indirect population, intervention, control, outcomes), publication bias, and imprecision (e.g. wide confidence intervals, single trial). Imprecision was determined principally by a small number of studies for a comparison (two or fewer studies) and fewer than 100 events for that comparison. We used the GRADEproGDT software to produce the Summary of Findings Tables. </p> <p><b>Cost</b> </p> <p>Cost estimates were determined by obtaining information from American retail pharmacies (i.e. GoodRx which is a compendium of six pharmacies and Walgreens/Boots) for a 10 day course of therapy, except for Teicoplann which as obtained from the British National Formulary. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004610-sec-0065" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004610-sec-0065"></div> <section id="CD004610-sec-0066"> <h3 class="title">Description of studies</h3> <section id="CD004610-sec-0067"> <h4 class="title">Results of the search</h4> <p>A literature search conducted on 26 January 2017 identified 3842 studies. After duplicates were removed a total of 2372 studies remained for review of titles and abstracts. Two authors independently reviewed the titles and abstracts of these studies and 43 studies were selected for full text review (See <a href="#CD004610-fig-0001">Figure 1</a>). Twenty‐one studies were subsequently excluded for reasons cited in the <a href="./references#CD004610-sec-0096" title="">Characteristics of excluded studies</a> table. In addition, two phase III trials of a new drug, cadazolid, were identified by searching trial registries (<a href="./references#CD004610-bbs2-0046" title="NCT01983683 . A multi‐center, randomized, double‐blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile‐associated diarrhea (CDAD). clinicaltrials.gov/ct2/show/NCT01983683 (accessed 7 November 2013). ">NCT01983683</a>; <a href="./references#CD004610-bbs2-0047" title="NCT01987895 . A multi‐center, randomized, double‐blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile‐associated diarrhea (CDAD). clinicaltrials.gov/ct2/show/NCT01987895 (accessed 7 November 2013). ">NCT01987895</a>). </p> <div class="figure" id="CD004610-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD004610-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD004610-sec-0068"> <h4 class="title">Included studies</h4> <p>In the original review there were nine included studies. The first update included three additional studies (<a href="./references#CD004610-bbs2-0010" title="LagrottereriaD , HolmesS , SmiejaM , SmaillF , LeeC . Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases2006;43(5):547‐52. ">Lagrotteria 2006</a>; <a href="./references#CD004610-bbs2-0016" title="MusherDM , LoganN , HamillRJ , DupontHL , LentnekA , GuptaA , et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clinical Infectious Diseases2006;43(4):421‐7. ">Musher 2006</a>; <a href="./references#CD004610-bbs2-0020" title="WulltM , OdenholtI . A double‐blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile‐associated diarrhoea. Journal of Antimicrobial Chemotherapy2004;54(1):211‐6. ">Wullt 2004</a>). The second update included three additional studies (<a href="./references#CD004610-bbs2-0012" title="LouieT , MillerM , DonskeyC , MullaneK , GoldsteinEJ . Clinical outcomes, safety and pharmacokinetics of OPT‐80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2009;53(1):223‐8. ">Louie 2009</a>; <a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a>; <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a>). In this third update seven more studies were added (<a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a>; <a href="./references#CD004610-bbs2-0007" title="GareyKW , GhantojiSS , ShahDN , HabibM , AroraV , JiangZD , et al. A randomized, double‐blind, placebo‐controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy2011;66(12):2850‐5. ">Garey 2011</a>; <a href="./references#CD004610-bbs2-0008" title="JohnsonS , LouieTJ , GerdingDN , CornelyOA , Chasan‐TaberS , FittsD , et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases2014;59(3):345‐54. ">Johnson 2014</a>; <a href="./references#CD004610-bbs2-0011" title="LeeCH , PatinoH , StevensC , RegeS , ChesnelL , LouieT , et al. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double‐blind, non‐inferiority, multicentre trial. Journal of Antimicrobial Chemotherapy2016;71(10):2964‐71. ">Lee 2016a</a>; <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a>; <a href="./references#CD004610-bbs2-0014" title="LouieT , NordCE , TalbotGH , WilcoxM , GerdingDN , BuitragoM , et al. Multicenter, double‐blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2015;59(10):6266‐73. ">Louie 2015</a>; <a href="./references#CD004610-bbs2-0015" title="MullaneK , LeeC , BresslerA , BuitragoM , WeissK , DabovicK , et al. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrobial Agents and Chemotherapy2015;59(3):1435‐40. ">Mullane 2015</a>). </p> <p>The 22 included studies (total 3215 participants) involve patients with diarrhoea who have recently received antibiotics for an infection other than <i>C. difficile</i>. The definition of diarrhoea ranged from at least two loose stools per day with an associated symptom such as rectal temperature &gt; 38 ºC (<a href="./references#CD004610-bbs2-0001" title="Anonymous . Treatment of Clostridium difficile‐associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group. Scandinavian Journal of Infectious Diseases1994;26(3):309‐16. ">Anonymous 1994</a>), to at least six loose stools in 36 hours (<a href="./references#CD004610-bbs2-0018" title="TeasleyDG , GerdingDN , OlsonMM , PetersonLR , GebhardRL , SchwartzMJ , et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile‐associated diarrhoea and colitis. Lancet1983;2(8358):1043‐6. ">Teasley 1983</a>; <a href="./references#CD004610-bbs2-0012" title="LouieT , MillerM , DonskeyC , MullaneK , GoldsteinEJ . Clinical outcomes, safety and pharmacokinetics of OPT‐80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2009;53(1):223‐8. ">Louie 2009</a>). All of the studies included a 'loose' or 'liquid' description of the stool in their definitions of diarrhoea. In terms of exclusion criteria, patients with HIV were only explicitly excluded from one study (<a href="./references#CD004610-bbs2-0001" title="Anonymous . Treatment of Clostridium difficile‐associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group. Scandinavian Journal of Infectious Diseases1994;26(3):309‐16. ">Anonymous 1994</a>). Pregnant women were excluded from two studies (<a href="./references#CD004610-bbs2-0001" title="Anonymous . Treatment of Clostridium difficile‐associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group. Scandinavian Journal of Infectious Diseases1994;26(3):309‐16. ">Anonymous 1994</a>; <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a>). All other studies had varying and vague exclusion criteria ranging from "other obvious cause of diarrhoea" (<a href="./references#CD004610-bbs2-0018" title="TeasleyDG , GerdingDN , OlsonMM , PetersonLR , GebhardRL , SchwartzMJ , et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile‐associated diarrhoea and colitis. Lancet1983;2(8358):1043‐6. ">Teasley 1983</a>) to "anatomic abnormality" (<a href="./references#CD004610-bbs2-0021" title="YoungGP , WardPB , BayleyN , GordonD , HigginsG , TrapaniJA , et al. Antibiotic‐associated colitis due to Clostridium difficile: double‐blind comparison of vancomycin with bacitracin. Gastroenterology1985;89(5):1038‐45. ">Young 1985</a>). Both <a href="./references#CD004610-bbs2-0012" title="LouieT , MillerM , DonskeyC , MullaneK , GoldsteinEJ . Clinical outcomes, safety and pharmacokinetics of OPT‐80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2009;53(1):223‐8. ">Louie 2009</a> and <a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a> excluded patients deemed clinically unstable and ''not expected to survive the study period''. <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> and most other authors excluded patients with suspected or proven life‐threatening intra‐abdominal complications. <a href="./references#CD004610-bbs2-0008" title="JohnsonS , LouieTJ , GerdingDN , CornelyOA , Chasan‐TaberS , FittsD , et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases2014;59(3):345‐54. ">Johnson 2014</a> accepted a positive endoscopy at enrolment as long as a positive toxin assay followed. <a href="./references#CD004610-bbs2-0015" title="MullaneK , LeeC , BresslerA , BuitragoM , WeissK , DabovicK , et al. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrobial Agents and Chemotherapy2015;59(3):1435‐40. ">Mullane 2015</a> excluded patients if they had 12 or more stools per day. Among the seven new studies only two specifically excluded patients with Crohn's disease or ulcerative colitis (<a href="./references#CD004610-bbs2-0011" title="LeeCH , PatinoH , StevensC , RegeS , ChesnelL , LouieT , et al. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double‐blind, non‐inferiority, multicentre trial. Journal of Antimicrobial Chemotherapy2016;71(10):2964‐71. ">Lee 2016a</a>; <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a>). In fact patients in all 22 included studies were well enough to tolerate oral medication. None of the prescribed antibiotics were given intravenously. </p> <p>The studies used different methods for detecting CDI. <a href="./references#CD004610-bbs2-0018" title="TeasleyDG , GerdingDN , OlsonMM , PetersonLR , GebhardRL , SchwartzMJ , et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile‐associated diarrhoea and colitis. Lancet1983;2(8358):1043‐6. ">Teasley 1983</a> defined <i>C. difficile</i> disease as stool being positive for <i>C. difficile</i> by culture or cytotoxin assay, or by the presence of pseudomembranes on endoscopy. Stool was tested for other enteric pathogens, but the authors did not comment on the presence or absence of these pathogens. <a href="./references#CD004610-bbs2-0021" title="YoungGP , WardPB , BayleyN , GordonD , HigginsG , TrapaniJA , et al. Antibiotic‐associated colitis due to Clostridium difficile: double‐blind comparison of vancomycin with bacitracin. Gastroenterology1985;89(5):1038‐45. ">Young 1985</a> and <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> defined CDI in the same manner as <a href="./references#CD004610-bbs2-0018" title="TeasleyDG , GerdingDN , OlsonMM , PetersonLR , GebhardRL , SchwartzMJ , et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile‐associated diarrhoea and colitis. Lancet1983;2(8358):1043‐6. ">Teasley 1983</a>. <a href="./references#CD004610-bbs2-0021" title="YoungGP , WardPB , BayleyN , GordonD , HigginsG , TrapaniJA , et al. Antibiotic‐associated colitis due to Clostridium difficile: double‐blind comparison of vancomycin with bacitracin. Gastroenterology1985;89(5):1038‐45. ">Young 1985</a> tested for the presence of other enteric pathogens and excluded patients if their stool tested positive for any other pathogen. <a href="./references#CD004610-bbs2-0005" title="DudleyMN , McLaughlinJC , CarringtonG , FrickJ , NightingaleCH , QuintilianiR . Oral bacitracin vs vancomycin therapy for Clostridium difficile‐induced diarrhea. A randomized double‐blind trial. Archives of Internal Medicine1986;146(6):1101‐4. ">Dudley 1986</a> and <a href="./references#CD004610-bbs2-0006" title="FeketyR , SilvaJ , KauffmanC , BuggyB , DeeryHG . Treatment of antibiotic‐associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. American Journal of Medicine1989;86(1):15‐9. ">Fekety 1989</a> and <a href="./references#CD004610-bbs2-0012" title="LouieT , MillerM , DonskeyC , MullaneK , GoldsteinEJ . Clinical outcomes, safety and pharmacokinetics of OPT‐80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2009;53(1):223‐8. ">Louie 2009</a> defined <i>C. difficile</i> disease by both culture or cytotoxin assay. <a href="./references#CD004610-bbs2-0005" title="DudleyMN , McLaughlinJC , CarringtonG , FrickJ , NightingaleCH , QuintilianiR . Oral bacitracin vs vancomycin therapy for Clostridium difficile‐induced diarrhea. A randomized double‐blind trial. Archives of Internal Medicine1986;146(6):1101‐4. ">Dudley 1986</a> and <a href="./references#CD004610-bbs2-0006" title="FeketyR , SilvaJ , KauffmanC , BuggyB , DeeryHG . Treatment of antibiotic‐associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. American Journal of Medicine1989;86(1):15‐9. ">Fekety 1989</a> did not test for the presence of other enteric pathogens. <a href="./references#CD004610-bbs2-0004" title="DeLallaF , NicolinR , RinaldiE , ScarpelliniP , RigoliR , ManfrinV , et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile‐associated diarrhea. Antimicrobial Agents and Chemotherapy1992;36(10):2192‐6. ">De Lalla 1992</a> defined <i>C. difficile</i> disease as stool being positive for cytotoxin, culture and evidence of colitis on endoscopy. <a href="./references#CD004610-bbs2-0004" title="DeLallaF , NicolinR , RinaldiE , ScarpelliniP , RigoliR , ManfrinV , et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile‐associated diarrhea. Antimicrobial Agents and Chemotherapy1992;36(10):2192‐6. ">De Lalla 1992</a> excluded patients if their stool tested positive for any other pathogen. <a href="./references#CD004610-bbs2-0019" title="WenischC , ParschalkB , HasenhundlM , HirschlAM , GraningerW . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases1996;22(5):813‐8. ">Wenisch 1996</a> defined <i>C. difficile</i> disease as stool positive for cytotoxin or endoscopic evidence of colitis and fecal leukocytes. <a href="./references#CD004610-bbs2-0019" title="WenischC , ParschalkB , HasenhundlM , HirschlAM , GraningerW . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases1996;22(5):813‐8. ">Wenisch 1996</a> did not perform stool culture on any of the study patients. The Swedish CDI study defined <i>C. difficile</i> disease as being positive for cytotoxin or culture or both and excluded patients if their stool tested positive for any other pathogen (<a href="./references#CD004610-bbs2-0001" title="Anonymous . Treatment of Clostridium difficile‐associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group. Scandinavian Journal of Infectious Diseases1994;26(3):309‐16. ">Anonymous 1994</a>). Eight studies used toxin assay and symptomatic diarrhoea to define <i>C. difficile</i> disease (<a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a>; <a href="./references#CD004610-bbs2-0007" title="GareyKW , GhantojiSS , ShahDN , HabibM , AroraV , JiangZD , et al. A randomized, double‐blind, placebo‐controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy2011;66(12):2850‐5. ">Garey 2011</a>; <a href="./references#CD004610-bbs2-0008" title="JohnsonS , LouieTJ , GerdingDN , CornelyOA , Chasan‐TaberS , FittsD , et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases2014;59(3):345‐54. ">Johnson 2014</a>; <a href="./references#CD004610-bbs2-0010" title="LagrottereriaD , HolmesS , SmiejaM , SmaillF , LeeC . Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases2006;43(5):547‐52. ">Lagrotteria 2006</a>; <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a>; <a href="./references#CD004610-bbs2-0016" title="MusherDM , LoganN , HamillRJ , DupontHL , LentnekA , GuptaA , et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clinical Infectious Diseases2006;43(4):421‐7. ">Musher 2006</a>; <a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a>; <a href="./references#CD004610-bbs2-0020" title="WulltM , OdenholtI . A double‐blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile‐associated diarrhoea. Journal of Antimicrobial Chemotherapy2004;54(1):211‐6. ">Wullt 2004</a>). Endoscopic evidence of pseudomembranous colitis was used in <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a>, <a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a> and <a href="./references#CD004610-bbs2-0008" title="JohnsonS , LouieTJ , GerdingDN , CornelyOA , Chasan‐TaberS , FittsD , et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases2014;59(3):345‐54. ">Johnson 2014</a> for initial enrolment, but subsequent positive toxin assay was also required. </p> <p>Eighteen of the 22 included studies compared different antibiotics for the treatment of <i>C. difficile</i>‐associated diarrhoea. <a href="./references#CD004610-bbs2-0018" title="TeasleyDG , GerdingDN , OlsonMM , PetersonLR , GebhardRL , SchwartzMJ , et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile‐associated diarrhoea and colitis. Lancet1983;2(8358):1043‐6. ">Teasley 1983</a> compared oral vancomycin 500 mg four times a day for 10 days with oral metronidazole 250 mg four times a day for 10 days. <a href="./references#CD004610-bbs2-0021" title="YoungGP , WardPB , BayleyN , GordonD , HigginsG , TrapaniJA , et al. Antibiotic‐associated colitis due to Clostridium difficile: double‐blind comparison of vancomycin with bacitracin. Gastroenterology1985;89(5):1038‐45. ">Young 1985</a> compared oral vancomycin 125 mg four times a day for 7 days with oral bacitracin 20,000 units four times a day for 7 days. <a href="./references#CD004610-bbs2-0005" title="DudleyMN , McLaughlinJC , CarringtonG , FrickJ , NightingaleCH , QuintilianiR . Oral bacitracin vs vancomycin therapy for Clostridium difficile‐induced diarrhea. A randomized double‐blind trial. Archives of Internal Medicine1986;146(6):1101‐4. ">Dudley 1986</a> compared oral vancomycin 500 mg four times a day for 10 days with oral bacitracin 25,000 units four times a day for 10 days. <a href="./references#CD004610-bbs2-0004" title="DeLallaF , NicolinR , RinaldiE , ScarpelliniP , RigoliR , ManfrinV , et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile‐associated diarrhea. Antimicrobial Agents and Chemotherapy1992;36(10):2192‐6. ">De Lalla 1992</a> compared oral vancomycin 500 mg four times a day for 10 days with oral teicoplanin 100 mg two times a day for 10 days. <a href="./references#CD004610-bbs2-0019" title="WenischC , ParschalkB , HasenhundlM , HirschlAM , GraningerW . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases1996;22(5):813‐8. ">Wenisch 1996</a> compared four antibiotics: oral vancomycin 500 mg three times a day for 10 days with oral metronidazole 500 mg three times a day for 10 days with oral fusidic acid 500 mg three times a day for 10 days with oral teicoplanin 400 mg two times a day for 10 days. <a href="./references#CD004610-bbs2-0020" title="WulltM , OdenholtI . A double‐blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile‐associated diarrhoea. Journal of Antimicrobial Chemotherapy2004;54(1):211‐6. ">Wullt 2004</a> compared 250 mg of fusidic acid three times per day to 400 mg of metronidazole three times per day for 7 days each. <a href="./references#CD004610-bbs2-0016" title="MusherDM , LoganN , HamillRJ , DupontHL , LentnekA , GuptaA , et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clinical Infectious Diseases2006;43(4):421‐7. ">Musher 2006</a> compared 250 mg of metronidazole four times per day for 10 days to 500 mg of nitazoxanide twice a day given for either 7 or 10 days. <a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a> compared 125mg of vancomycin four times per day for 10 days to 500 mg of nitazoxanide twice a day for 10 days. <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> compared 125 mg of vancomycin four times per day with 250 mg of metronidazole four times per day for 10 days. <a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a> and <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a> published studies of identical design in two large diverse populations comparing an oral 10 day course of fidaxomicin 200 mg every 12 hours to vancomycin 125 mg every 6 hours. <a href="./references#CD004610-bbs2-0008" title="JohnsonS , LouieTJ , GerdingDN , CornelyOA , Chasan‐TaberS , FittsD , et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases2014;59(3):345‐54. ">Johnson 2014</a> was a three armed study, whose principal objective was to assess the efficacy of Tolevamer, a resin that binds <i>Clostridium difficile</i> toxin. The other two arms of this multi‐institutional, multinational study compared the efficacy of vancomycin and metronidazole to Tolevamer and thus also to each other. Due to its size, this study added significantly to the data for the comparison of metronidazole to vancomycin. The Tolevamer arm of this study was not included in this review. Two other new antibiotics were reported by <a href="./references#CD004610-bbs2-0014" title="LouieT , NordCE , TalbotGH , WilcoxM , GerdingDN , BuitragoM , et al. Multicenter, double‐blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2015;59(10):6266‐73. ">Louie 2015</a> (Cadazolid) and <a href="./references#CD004610-bbs2-0015" title="MullaneK , LeeC , BresslerA , BuitragoM , WeissK , DabovicK , et al. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrobial Agents and Chemotherapy2015;59(3):1435‐40. ">Mullane 2015</a> (LFF571). Neither of these recent studies stratified by disease severity before or after randomisation. The Cadazolid study reported three different dose groups separately but since the results were similar for the outcome assessment these groups were combined for the comparison to vancomycin. <a href="./references#CD004610-bbs2-0011" title="LeeCH , PatinoH , StevensC , RegeS , ChesnelL , LouieT , et al. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double‐blind, non‐inferiority, multicentre trial. Journal of Antimicrobial Chemotherapy2016;71(10):2964‐71. ">Lee 2016a</a> compared two doses of a new antibiotic, surotomycin, to vancomycin in a non‐inferiority trial, similar to <a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a> and <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a>). </p> <p><a href="./references#CD004610-bbs2-0007" title="GareyKW , GhantojiSS , ShahDN , HabibM , AroraV , JiangZD , et al. A randomized, double‐blind, placebo‐controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy2011;66(12):2850‐5. ">Garey 2011</a> studied the effect of rifaximin 400 mg three times daily for 20 days compared to placebo in a group who had had CDI successfully treated with either metronidazole or vancomycin (the choice of these antibiotics being physician choice and non‐random) in order to prevent a highly likely occurrence, relapse of CDI. Strictly speaking this is not an eligible trial, in that it assesses a prophylactic intervention. However its goal was to define an antibiotic combination the best achieves a long term cure of CDI , perhaps more comparable in that regard to <a href="./references#CD004610-bbs2-0031" title="JohnsonS , HomannSR , BettinKM , QuickJN , ClabotsCR , PetersonLR , et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo‐controlled trial. Annals of Internal Medicine1992;117(4):297‐302. ">Johnson 1992</a>. </p> <p>The Swedish CDI study was a dose finding study which compared oral teicoplanin given at a constant daily dose but in differing dose schedules throughout the day (<a href="./references#CD004610-bbs2-0001" title="Anonymous . Treatment of Clostridium difficile‐associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group. Scandinavian Journal of Infectious Diseases1994;26(3):309‐16. ">Anonymous 1994</a>, also cited in some sources as Wistrom 1994). <a href="./references#CD004610-bbs2-0006" title="FeketyR , SilvaJ , KauffmanC , BuggyB , DeeryHG . Treatment of antibiotic‐associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. American Journal of Medicine1989;86(1):15‐9. ">Fekety 1989</a> performed a dosage‐finding study for oral vancomycin by comparing 125 mg four times a day with 500 mg four times a day for an average of 10 days. <a href="./references#CD004610-bbs2-0012" title="LouieT , MillerM , DonskeyC , MullaneK , GoldsteinEJ . Clinical outcomes, safety and pharmacokinetics of OPT‐80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2009;53(1):223‐8. ">Louie 2009</a> compared fidaxomicin (OPT‐80) given at either 50 mg, 100 mg or 200 mg doses twice daily for ten days. Only one study was placebo‐controlled and compared vancomycin to placebo (<a href="./references#CD004610-bbs2-0009" title="KeighleyMR , BurdonDW , ArabiY , WilliamsJA , ThompsonH , YoungsD , et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. British Medical Journal1978;2(6153):1667‐9. ">Keighley 1978</a>). </p> <p>In addition to treating CDI with antibiotics, the above studies also dealt with the initial, offending antibiotic in different ways. Only three studies explicitly reported that all initial antibiotics were stopped (<a href="./references#CD004610-bbs2-0019" title="WenischC , ParschalkB , HasenhundlM , HirschlAM , GraningerW . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases1996;22(5):813‐8. ">Wenisch 1996</a>; <a href="./references#CD004610-bbs2-0021" title="YoungGP , WardPB , BayleyN , GordonD , HigginsG , TrapaniJA , et al. Antibiotic‐associated colitis due to Clostridium difficile: double‐blind comparison of vancomycin with bacitracin. Gastroenterology1985;89(5):1038‐45. ">Young 1985</a>; <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a>). Three of the other studies made attempts to stop the initial antibiotics, but these antibiotics were continued if deemed essential to the patient's clinical treatment (<a href="./references#CD004610-bbs2-0001" title="Anonymous . Treatment of Clostridium difficile‐associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group. Scandinavian Journal of Infectious Diseases1994;26(3):309‐16. ">Anonymous 1994</a>; <a href="./references#CD004610-bbs2-0005" title="DudleyMN , McLaughlinJC , CarringtonG , FrickJ , NightingaleCH , QuintilianiR . Oral bacitracin vs vancomycin therapy for Clostridium difficile‐induced diarrhea. A randomized double‐blind trial. Archives of Internal Medicine1986;146(6):1101‐4. ">Dudley 1986</a>; <a href="./references#CD004610-bbs2-0018" title="TeasleyDG , GerdingDN , OlsonMM , PetersonLR , GebhardRL , SchwartzMJ , et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile‐associated diarrhoea and colitis. Lancet1983;2(8358):1043‐6. ">Teasley 1983</a>). <a href="./references#CD004610-bbs2-0012" title="LouieT , MillerM , DonskeyC , MullaneK , GoldsteinEJ . Clinical outcomes, safety and pharmacokinetics of OPT‐80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2009;53(1):223‐8. ">Louie 2009</a> excluded any patients requiring concurrent antibiotic therapy, but made no reference to the initial antibiotics used in the included participants. The remaining studies either stated that the initial antibiotic was either stopped or changed (<a href="./references#CD004610-bbs2-0006" title="FeketyR , SilvaJ , KauffmanC , BuggyB , DeeryHG . Treatment of antibiotic‐associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. American Journal of Medicine1989;86(1):15‐9. ">Fekety 1989</a>) or did not make any reference to the initial antibiotic at all (<a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a>; <a href="./references#CD004610-bbs2-0004" title="DeLallaF , NicolinR , RinaldiE , ScarpelliniP , RigoliR , ManfrinV , et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile‐associated diarrhea. Antimicrobial Agents and Chemotherapy1992;36(10):2192‐6. ">De Lalla 1992</a>; <a href="./references#CD004610-bbs2-0007" title="GareyKW , GhantojiSS , ShahDN , HabibM , AroraV , JiangZD , et al. A randomized, double‐blind, placebo‐controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy2011;66(12):2850‐5. ">Garey 2011</a>; <a href="./references#CD004610-bbs2-0008" title="JohnsonS , LouieTJ , GerdingDN , CornelyOA , Chasan‐TaberS , FittsD , et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases2014;59(3):345‐54. ">Johnson 2014</a>; <a href="./references#CD004610-bbs2-0010" title="LagrottereriaD , HolmesS , SmiejaM , SmaillF , LeeC . Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases2006;43(5):547‐52. ">Lagrotteria 2006</a>; <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a>; <a href="./references#CD004610-bbs2-0016" title="MusherDM , LoganN , HamillRJ , DupontHL , LentnekA , GuptaA , et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clinical Infectious Diseases2006;43(4):421‐7. ">Musher 2006</a>; <a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a>; <a href="./references#CD004610-bbs2-0020" title="WulltM , OdenholtI . A double‐blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile‐associated diarrhoea. Journal of Antimicrobial Chemotherapy2004;54(1):211‐6. ">Wullt 2004</a>; <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a>). </p> <p><a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> defined cure as a combination of resolution of diarrhoea and conversion of stool to toxin negative, whereas other authors reported these outcomes separately, or did not report bacteriologic cure at all. <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> is the first study to stratify patients (perhaps after randomisation) by disease severity when assessing the relative efficacy of metronidazole and vancomycin. This is of importance because this general concept of efficacy assessment has been adopted in subsequent studies (<a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a>; <a href="./references#CD004610-bbs2-0008" title="JohnsonS , LouieTJ , GerdingDN , CornelyOA , Chasan‐TaberS , FittsD , et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases2014;59(3):345‐54. ">Johnson 2014</a>; <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a>; <a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a>), and three major guideline publications including the UK Health Protection Agency (<a href="./references#CD004610-bbs2-0069" title="Health Protection Agency of the Department of Health, UK . Clostridium difficile infection: How to deal with the problem. www.gov.uk/government/uploads/system/uploads/attachment_data/file/340851/Clostridium_difficile_infection_how_to_deal_with_the_problem.pdf (accessed 26 January 2017). ">HPA 2008</a>), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) (<a href="./references#CD004610-bbs2-0055" title="BauerMP , KuijperEJ , vanDisselJT . European society of clinical microbiology and infectious diseases (ESCMID): treatment guidance for Clostridium difficile infection (CDI). Clinical Microbiology and Infection2009;15(12):1067‐79. ">Bauer 2009</a>), and the combined Infectious Diseases Society of America (IDSA), and the Society for Healthcare Epidemiology of America (SHEA), which is reported on the Centers for Disease Control (CDC) website (<a href="./references#CD004610-bbs2-0058" title="CohenSH , GerdingDN , JohnsonS , KellyCP , LooVG , McDonaldLC , et al. Clinical practice guidelines for clostridium difficile infection in adults: 2010 update for the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology2010;31(5):431‐55. ">Cohen 2010</a>). No study since <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> has specified in its methods that patients' randomisation was stratified by disease severity, although four more studies reported response to treatment by severity classes in post hoc subgroup analyses (<a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a>; <a href="./references#CD004610-bbs2-0008" title="JohnsonS , LouieTJ , GerdingDN , CornelyOA , Chasan‐TaberS , FittsD , et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases2014;59(3):345‐54. ">Johnson 2014</a>; <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a>; <a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a>). None of the included studies stratified the randomisation of patients based on cessation or continuation of the antibiotic that caused the CDI. </p> </section> <section id="CD004610-sec-0069"> <h4 class="title">Excluded studies</h4> <p>Excluded studies and the reasons for exclusion can be found in the <a href="./references#CD004610-sec-0096" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD004610-sec-0070"> <h3 class="title">Risk of bias in included studies</h3> <p>The results of the risk of bias analysis are presented in <a href="#CD004610-fig-0002">Figure 2</a> and <a href="#CD004610-fig-0003">Figure 3</a>. Quality concerns include unclear allocation concealment, unclear generation of the allocation sequence and blinding of researchers and participants. Only 11 of the 22 studies reported adequate allocation concealment (<a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a>; <a href="./references#CD004610-bbs2-0005" title="DudleyMN , McLaughlinJC , CarringtonG , FrickJ , NightingaleCH , QuintilianiR . Oral bacitracin vs vancomycin therapy for Clostridium difficile‐induced diarrhea. A randomized double‐blind trial. Archives of Internal Medicine1986;146(6):1101‐4. ">Dudley 1986</a>; <a href="./references#CD004610-bbs2-0007" title="GareyKW , GhantojiSS , ShahDN , HabibM , AroraV , JiangZD , et al. A randomized, double‐blind, placebo‐controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy2011;66(12):2850‐5. ">Garey 2011</a>; <a href="./references#CD004610-bbs2-0009" title="KeighleyMR , BurdonDW , ArabiY , WilliamsJA , ThompsonH , YoungsD , et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. British Medical Journal1978;2(6153):1667‐9. ">Keighley 1978</a>; <a href="./references#CD004610-bbs2-0010" title="LagrottereriaD , HolmesS , SmiejaM , SmaillF , LeeC . Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases2006;43(5):547‐52. ">Lagrotteria 2006</a>; <a href="./references#CD004610-bbs2-0011" title="LeeCH , PatinoH , StevensC , RegeS , ChesnelL , LouieT , et al. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double‐blind, non‐inferiority, multicentre trial. Journal of Antimicrobial Chemotherapy2016;71(10):2964‐71. ">Lee 2016a</a>; <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a>; <a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a>; <a href="./references#CD004610-bbs2-0020" title="WulltM , OdenholtI . A double‐blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile‐associated diarrhoea. Journal of Antimicrobial Chemotherapy2004;54(1):211‐6. ">Wullt 2004</a>; <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a>). Twelve studies adequately explained the method used for random sequence generation (<a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a>; <a href="./references#CD004610-bbs2-0005" title="DudleyMN , McLaughlinJC , CarringtonG , FrickJ , NightingaleCH , QuintilianiR . Oral bacitracin vs vancomycin therapy for Clostridium difficile‐induced diarrhea. A randomized double‐blind trial. Archives of Internal Medicine1986;146(6):1101‐4. ">Dudley 1986</a>; <a href="./references#CD004610-bbs2-0006" title="FeketyR , SilvaJ , KauffmanC , BuggyB , DeeryHG . Treatment of antibiotic‐associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. American Journal of Medicine1989;86(1):15‐9. ">Fekety 1989</a>; <a href="./references#CD004610-bbs2-0007" title="GareyKW , GhantojiSS , ShahDN , HabibM , AroraV , JiangZD , et al. A randomized, double‐blind, placebo‐controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy2011;66(12):2850‐5. ">Garey 2011</a>; <a href="./references#CD004610-bbs2-0010" title="LagrottereriaD , HolmesS , SmiejaM , SmaillF , LeeC . Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases2006;43(5):547‐52. ">Lagrotteria 2006</a>; <a href="./references#CD004610-bbs2-0012" title="LouieT , MillerM , DonskeyC , MullaneK , GoldsteinEJ . Clinical outcomes, safety and pharmacokinetics of OPT‐80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2009;53(1):223‐8. ">Louie 2009</a>; <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a>; <a href="./references#CD004610-bbs2-0014" title="LouieT , NordCE , TalbotGH , WilcoxM , GerdingDN , BuitragoM , et al. Multicenter, double‐blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2015;59(10):6266‐73. ">Louie 2015</a>; <a href="./references#CD004610-bbs2-0015" title="MullaneK , LeeC , BresslerA , BuitragoM , WeissK , DabovicK , et al. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrobial Agents and Chemotherapy2015;59(3):1435‐40. ">Mullane 2015</a>; <a href="./references#CD004610-bbs2-0019" title="WenischC , ParschalkB , HasenhundlM , HirschlAM , GraningerW . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases1996;22(5):813‐8. ">Wenisch 1996</a>; <a href="./references#CD004610-bbs2-0020" title="WulltM , OdenholtI . A double‐blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile‐associated diarrhoea. Journal of Antimicrobial Chemotherapy2004;54(1):211‐6. ">Wullt 2004</a>; <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a>). Eleven studies clearly stated that the researchers and the subjects were both blinded (<a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a>; <a href="./references#CD004610-bbs2-0007" title="GareyKW , GhantojiSS , ShahDN , HabibM , AroraV , JiangZD , et al. A randomized, double‐blind, placebo‐controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy2011;66(12):2850‐5. ">Garey 2011</a>; <a href="./references#CD004610-bbs2-0008" title="JohnsonS , LouieTJ , GerdingDN , CornelyOA , Chasan‐TaberS , FittsD , et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases2014;59(3):345‐54. ">Johnson 2014</a>; <a href="./references#CD004610-bbs2-0011" title="LeeCH , PatinoH , StevensC , RegeS , ChesnelL , LouieT , et al. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double‐blind, non‐inferiority, multicentre trial. Journal of Antimicrobial Chemotherapy2016;71(10):2964‐71. ">Lee 2016a</a>; <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a>; <a href="./references#CD004610-bbs2-0014" title="LouieT , NordCE , TalbotGH , WilcoxM , GerdingDN , BuitragoM , et al. Multicenter, double‐blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2015;59(10):6266‐73. ">Louie 2015</a>; <a href="./references#CD004610-bbs2-0015" title="MullaneK , LeeC , BresslerA , BuitragoM , WeissK , DabovicK , et al. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrobial Agents and Chemotherapy2015;59(3):1435‐40. ">Mullane 2015</a>; <a href="./references#CD004610-bbs2-0016" title="MusherDM , LoganN , HamillRJ , DupontHL , LentnekA , GuptaA , et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clinical Infectious Diseases2006;43(4):421‐7. ">Musher 2006</a>; <a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a>; <a href="./references#CD004610-bbs2-0020" title="WulltM , OdenholtI . A double‐blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile‐associated diarrhoea. Journal of Antimicrobial Chemotherapy2004;54(1):211‐6. ">Wullt 2004</a>; <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a>). Two studies stated that patients were blinded, but it was unclear if outcome assessors were blinded (<a href="./references#CD004610-bbs2-0005" title="DudleyMN , McLaughlinJC , CarringtonG , FrickJ , NightingaleCH , QuintilianiR . Oral bacitracin vs vancomycin therapy for Clostridium difficile‐induced diarrhea. A randomized double‐blind trial. Archives of Internal Medicine1986;146(6):1101‐4. ">Dudley 1986</a>; <a href="./references#CD004610-bbs2-0021" title="YoungGP , WardPB , BayleyN , GordonD , HigginsG , TrapaniJA , et al. Antibiotic‐associated colitis due to Clostridium difficile: double‐blind comparison of vancomycin with bacitracin. Gastroenterology1985;89(5):1038‐45. ">Young 1985</a>). Outcome assessors were not blinded in the <a href="./references#CD004610-bbs2-0006" title="FeketyR , SilvaJ , KauffmanC , BuggyB , DeeryHG . Treatment of antibiotic‐associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. American Journal of Medicine1989;86(1):15‐9. ">Fekety 1989</a> study. Patients were not blinded in the <a href="./references#CD004610-bbs2-0010" title="LagrottereriaD , HolmesS , SmiejaM , SmaillF , LeeC . Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases2006;43(5):547‐52. ">Lagrotteria 2006</a> study. <a href="./references#CD004610-bbs2-0012" title="LouieT , MillerM , DonskeyC , MullaneK , GoldsteinEJ . Clinical outcomes, safety and pharmacokinetics of OPT‐80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2009;53(1):223‐8. ">Louie 2009</a> was a dose finding study and was not blinded. The <a href="./references#CD004610-bbs2-0019" title="WenischC , ParschalkB , HasenhundlM , HirschlAM , GraningerW . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases1996;22(5):813‐8. ">Wenisch 1996</a>, <a href="./references#CD004610-bbs2-0004" title="DeLallaF , NicolinR , RinaldiE , ScarpelliniP , RigoliR , ManfrinV , et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile‐associated diarrhea. Antimicrobial Agents and Chemotherapy1992;36(10):2192‐6. ">De Lalla 1992</a> and <a href="./references#CD004610-bbs2-0002" title="BoeroM , BertiE , MorgandoA , VermeG . Treatment of pseudomembranous colitis: a randomized controlled trial with rifaximin vs vancomycin [Terapia della colite da Clostridium difficile: risultati di uno studio randomizzato aperto rifaximina vs. vancomicina]. Microbiologia Medica1990;5(2):74‐7. ">Boero 1990</a> studies were not blinded. Attempts were made to contact the authors to clarify these issues and as of the submission of this review correspondence was not established. </p> <div class="figure" id="CD004610-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD004610-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD004610-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD004610-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <p>The included studies have additional quality issues. One diagnostic concern is that 17 of the 22 included studies used <i>C. difficile</i> cytotoxin stool assay as the means of identifying infected patients. Two other studies required stool positive for cytotoxin and growth of <i>C. difficile</i> on culture to establish the presence of CDI (<a href="./references#CD004610-bbs2-0004" title="DeLallaF , NicolinR , RinaldiE , ScarpelliniP , RigoliR , ManfrinV , et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile‐associated diarrhea. Antimicrobial Agents and Chemotherapy1992;36(10):2192‐6. ">De Lalla 1992</a>; <a href="./references#CD004610-bbs2-0006" title="FeketyR , SilvaJ , KauffmanC , BuggyB , DeeryHG . Treatment of antibiotic‐associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. American Journal of Medicine1989;86(1):15‐9. ">Fekety 1989</a>). Although it was not specifically reported in the text how <i>C. difficile</i> was identified as the cause of CDI in the <a href="./references#CD004610-bbs2-0011" title="LeeCH , PatinoH , StevensC , RegeS , ChesnelL , LouieT , et al. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double‐blind, non‐inferiority, multicentre trial. Journal of Antimicrobial Chemotherapy2016;71(10):2964‐71. ">Lee 2016a</a> study, the strain of <i>C. difficile</i> in each patients was reported in the demographics. <a href="./references#CD004610-bbs2-0009" title="KeighleyMR , BurdonDW , ArabiY , WilliamsJA , ThompsonH , YoungsD , et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. British Medical Journal1978;2(6153):1667‐9. ">Keighley 1978</a> separated patients who had positive cytotoxin from those patients who had positive cultures. However, the most important quality issue encountered in this review was that no study in which there were dropouts included those dropouts in their analyses, so effectively all participants were analysed as treated. In some studies this had a major impact, since randomisation occurred before disease confirmation, and participants were eliminated after randomisation when they were found not to have CDI. In some cases this was as low as 2% of those randomised (<a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a>), however, in several studies the dropout rate was as high as 50% due to exclusions after randomisation (<a href="./references#CD004610-bbs2-0001" title="Anonymous . Treatment of Clostridium difficile‐associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group. Scandinavian Journal of Infectious Diseases1994;26(3):309‐16. ">Anonymous 1994</a>; <a href="./references#CD004610-bbs2-0005" title="DudleyMN , McLaughlinJC , CarringtonG , FrickJ , NightingaleCH , QuintilianiR . Oral bacitracin vs vancomycin therapy for Clostridium difficile‐induced diarrhea. A randomized double‐blind trial. Archives of Internal Medicine1986;146(6):1101‐4. ">Dudley 1986</a>; <a href="./references#CD004610-bbs2-0009" title="KeighleyMR , BurdonDW , ArabiY , WilliamsJA , ThompsonH , YoungsD , et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. British Medical Journal1978;2(6153):1667‐9. ">Keighley 1978</a>). For all studies in this review dropouts were considered to be treatment failures. </p> <p>For the initial diagnosis of CDI, most included studies did not exclude the presence of other pathogens in the stool as the cause of diarrhoea. It is possible that a patient could have been infected with both <i>C. difficile</i> and another enteric pathogen. The studies do not consistently state whether the initial, offending antibiotic was stopped and if it was stopped, whether a different antibiotic was started in its place. Although <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> screened stool samples for <i>Shigella</i> , <i>Salmonella</i> and <i>Campylobacter</i>, all patients were negative for these microbes in this study. Additionally, only <a href="./references#CD004610-bbs2-0021" title="YoungGP , WardPB , BayleyN , GordonD , HigginsG , TrapaniJA , et al. Antibiotic‐associated colitis due to Clostridium difficile: double‐blind comparison of vancomycin with bacitracin. Gastroenterology1985;89(5):1038‐45. ">Young 1985</a> controlled for patients whose diarrhoea rapidly resolved on its own with the removal of the initial antibiotic by including only those patients with persistent symptoms. For these patients the diarrhoea may not have been caused by <i>C. difficile,</i> although it was present in the stool, or the bacterium was successfully purged by the patient. Recent studies relied on positive toxin assay and diarrhoea alone to make the diagnosis. Some studies included endoscopic confirmation of pseudomembranes, although this was not uniformly done even within these studies. <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> did include pre‐existing pseudomembrane checks, although no patients had pre‐existing pseudomembranous colitis in this study. </p> <p>Each specific trial also had its own unique quality issues as well. In the <a href="./references#CD004610-bbs2-0018" title="TeasleyDG , GerdingDN , OlsonMM , PetersonLR , GebhardRL , SchwartzMJ , et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile‐associated diarrhoea and colitis. Lancet1983;2(8358):1043‐6. ">Teasley 1983</a> study which compared vancomycin to metronidazole, the offending antibiotics believed to have brought about the CDI were said to be discontinued unless they were "essential for treatment." This was also true and quantified by <a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a>, <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a> and <a href="./references#CD004610-bbs2-0008" title="JohnsonS , LouieTJ , GerdingDN , CornelyOA , Chasan‐TaberS , FittsD , et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases2014;59(3):345‐54. ">Johnson 2014</a> but not allocated to such treatment in a random manner. <a href="./references#CD004610-bbs2-0018" title="TeasleyDG , GerdingDN , OlsonMM , PetersonLR , GebhardRL , SchwartzMJ , et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile‐associated diarrhoea and colitis. Lancet1983;2(8358):1043‐6. ">Teasley 1983</a> did not indicate how many patients did not have their offending antibiotic discontinued. However these studies and others may confound the interpretation of results as the original antibiotic may have caused diarrhoea by a different mechanism. <a href="./references#CD004610-bbs2-0005" title="DudleyMN , McLaughlinJC , CarringtonG , FrickJ , NightingaleCH , QuintilianiR . Oral bacitracin vs vancomycin therapy for Clostridium difficile‐induced diarrhea. A randomized double‐blind trial. Archives of Internal Medicine1986;146(6):1101‐4. ">Dudley 1986</a> and <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> and <a href="./references#CD004610-bbs2-0008" title="JohnsonS , LouieTJ , GerdingDN , CornelyOA , Chasan‐TaberS , FittsD , et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases2014;59(3):345‐54. ">Johnson 2014</a> (although positive endoscopy at recruitment was required for inclusion) did not have test results for <i>C. difficile</i> in the stool until after randomisation. As a result, all of the patients with diarrhoea that were <i>C. difficile</i> negative were dropped from these studies. <a href="./references#CD004610-bbs2-0019" title="WenischC , ParschalkB , HasenhundlM , HirschlAM , GraningerW . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases1996;22(5):813‐8. ">Wenisch 1996</a> had a total of seven dropouts from all of the treatment arms combined. However, <a href="./references#CD004610-bbs2-0019" title="WenischC , ParschalkB , HasenhundlM , HirschlAM , GraningerW . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases1996;22(5):813‐8. ">Wenisch 1996</a> did not indicate the treatment allocation of these patients, therefore precluding an accurate intention‐to‐treat analysis of the results. In the Swedish CDI study there was an intermediate measure of cure called 'improvement,' but the criteria for improvement were never described (<a href="./references#CD004610-bbs2-0001" title="Anonymous . Treatment of Clostridium difficile‐associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group. Scandinavian Journal of Infectious Diseases1994;26(3):309‐16. ">Anonymous 1994</a>). For the purposes of this systematic review, a conservative approach was taken and the 'improved' patients were not considered to have their clinical symptoms resolved. <a href="./references#CD004610-bbs2-0006" title="FeketyR , SilvaJ , KauffmanC , BuggyB , DeeryHG . Treatment of antibiotic‐associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. American Journal of Medicine1989;86(1):15‐9. ">Fekety 1989</a> had a dropout rate of 18% and the duration of the antibiotic therapy was determined by each individual physician treating patients. The average duration of therapy was 10 days with a range of 5 to 15 days (<a href="./references#CD004610-bbs2-0006" title="FeketyR , SilvaJ , KauffmanC , BuggyB , DeeryHG . Treatment of antibiotic‐associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. American Journal of Medicine1989;86(1):15‐9. ">Fekety 1989</a>). Dropouts were 13% and 23% respectively in the <a href="./references#CD004610-bbs2-0020" title="WulltM , OdenholtI . A double‐blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile‐associated diarrhoea. Journal of Antimicrobial Chemotherapy2004;54(1):211‐6. ">Wullt 2004</a> and <a href="./references#CD004610-bbs2-0016" title="MusherDM , LoganN , HamillRJ , DupontHL , LentnekA , GuptaA , et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clinical Infectious Diseases2006;43(4):421‐7. ">Musher 2006</a> studies, making an intention‐to‐treat analysis difficult. However, both studies reported dropouts by allocation group. There were no dropouts in the smaller <a href="./references#CD004610-bbs2-0010" title="LagrottereriaD , HolmesS , SmiejaM , SmaillF , LeeC . Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases2006;43(5):547‐52. ">Lagrotteria 2006</a> study. <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> had a dropout rate of 12.8% (22/172), however, the study still achieved predetermined power. <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> also excluded "suspected or proven life‐threatening intra‐abdominal complications" as well as prescription of either vancomycin or metronidazole in the 14 days prior to enrolment. <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> retested stool for recurrence at 21 days after cure (defined as symptom‐free and toxin‐free stool at day 10). This protocol was not based on evidence, and it should be noted that current guidelines for management of asymptomatic carriers of <i>C. difficile</i> are conservative. Although <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> screened for prior antibiotic use, no data were reported on which antibiotics were used. Although <a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a> was a multi‐centre randomised trial, 37 of 50 patients came from the principal investigator's hospital. The study excluded patients undergoing enteral tube feeding. Another exclusion criterion was use of "any drug with anti‐<i>C. difficile</i> activity ‐ with the exception of ≤3 oral doses of metronidazole or vancomycin ‐ within 1 week" of entry. It should be noted that <a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a> had a dropout rate of 18.4% (9/49) and was terminated early due to "slower‐than‐expected recruitment". It also fell far short of its predetermined sample size of 350. </p> <p>Selective reporting bias was detected in only two studies (<a href="./references#CD004610-bbs2-0002" title="BoeroM , BertiE , MorgandoA , VermeG . Treatment of pseudomembranous colitis: a randomized controlled trial with rifaximin vs vancomycin [Terapia della colite da Clostridium difficile: risultati di uno studio randomizzato aperto rifaximina vs. vancomicina]. Microbiologia Medica1990;5(2):74‐7. ">Boero 1990</a>,<a href="./references#CD004610-bbs2-0006" title="FeketyR , SilvaJ , KauffmanC , BuggyB , DeeryHG . Treatment of antibiotic‐associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. American Journal of Medicine1989;86(1):15‐9. ">Fekety 1989</a>). None of the other studies reported very long follow up after innitial description of clinical response, varying from 14 (<a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a>) to 40 (<a href="./references#CD004610-bbs2-0020" title="WulltM , OdenholtI . A double‐blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile‐associated diarrhoea. Journal of Antimicrobial Chemotherapy2004;54(1):211‐6. ">Wullt 2004</a>) days. </p> <p><a href="./references#CD004610-bbs2-0012" title="LouieT , MillerM , DonskeyC , MullaneK , GoldsteinEJ . Clinical outcomes, safety and pharmacokinetics of OPT‐80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2009;53(1):223‐8. ">Louie 2009</a> was a phase IIa trial and was an open label study for mild to moderate <i>C. difficile</i> infection and excluded all patients with severe disease and those who were "not expected to survive the study period". While patients kept a symptom diary, they were only formally observed at study entry and at the end of treatment or withdrawal. </p> </section> <section id="CD004610-sec-0071"> <h3 class="title" id="CD004610-sec-0071">Effects of interventions</h3> <p>See: <a href="./full#CD004610-tbl-0001"><b>Summary of findings for the main comparison</b> Metronidazole versus vancomycin for <i>Clostridium difficile</i>‐associated diarrhoea in adults</a>; <a href="./full#CD004610-tbl-0002"><b>Summary of findings 2</b> Teicoplanin versus vancomycin for <i>Clostridium difficile</i>‐associated diarrhoea in adults</a>; <a href="./full#CD004610-tbl-0003"><b>Summary of findings 3</b> Fidaxomicin compared to vancomycin for <i>Clostridium difficile</i>‐associated diarrhoea in adults</a>; <a href="./full#CD004610-tbl-0004"><b>Summary of findings 4</b> Bacitracin versus vancomycin for <i>Clostridium difficile</i>‐associated diarrhoea in adults</a> </p> <p><b>Metronidazole versus vancomycin</b> <br/> Symptomatic cure was improved with vancomycin over metronidazole with the addition of the large study by <a href="./references#CD004610-bbs2-0008" title="JohnsonS , LouieTJ , GerdingDN , CornelyOA , Chasan‐TaberS , FittsD , et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases2014;59(3):345‐54. ">Johnson 2014</a>. Seventy‐two per cent (318/444) of metronidazole patients achieved symptomatic cure compared to 79% (339/428) of vancomycin patients (RR 0.90, 95% CI 0.84 to 0.97; <a href="./references#CD004610-fig-0004" title="">Analysis 1.1</a>; fixed‐effect; insignificant heterogeneity). A random‐effects model showed a non‐significant benefit for vancomycin (RR 0.92, 95% CI 0.82 to 1.04). We rated the strength of the evidence supporting the symptomatic cure outcome as moderate due to high risk of bias and due to the non‐reporting of additional pathogens that may have caused diarrhoea. Only two studies reported on bacteriologic cure (<a href="./references#CD004610-bbs2-0018" title="TeasleyDG , GerdingDN , OlsonMM , PetersonLR , GebhardRL , SchwartzMJ , et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile‐associated diarrhoea and colitis. Lancet1983;2(8358):1043‐6. ">Teasley 1983</a>; <a href="./references#CD004610-bbs2-0019" title="WenischC , ParschalkB , HasenhundlM , HirschlAM , GraningerW . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases1996;22(5):813‐8. ">Wenisch 1996</a>), and the strength of evidence for this outcome was very low due to high risk of bias (i.e. lack of blinding) and very serious imprecision (<a href="./references#CD004610-fig-0005" title="">Analysis 1.2</a>). Looking at the severity stratification reported by <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> (<a href="./references#CD004610-fig-0006" title="">Analysis 1.3</a>), the evidence was also very low due to high risk of bias and very serious imprecision (See <a href="./full#CD004610-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>One study presented an outcome not used in the other included studies (<a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a>) which was a combination of symptomatic and bacteriologic cure (<a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a>). Subsequent studies have only assessed bacteriologic evidence of CDI in patients with persistent or recurrent symptoms and therefore could not report bacteriologic cure (<a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a>; <a href="./references#CD004610-bbs2-0008" title="JohnsonS , LouieTJ , GerdingDN , CornelyOA , Chasan‐TaberS , FittsD , et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases2014;59(3):345‐54. ">Johnson 2014</a>; <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a>). <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> was also the first study to report differential efficacy of the two antibiotics based on disease severity. </p> <p><b>Bacitracin versus vancomycin</b> <br/> Vancomycin was also superior to bacitracin for achieving symptomatic cure. Twenty‐seven per cent (14/52) of bacitracin patients achieved symptomatic cure compared to 46% (24/52) vancomycin patients (RR 0.58, 95% CI 0.34 to 0.99; <a href="./references#CD004610-fig-0007" title="">Analysis 2.1</a>; no heterogeneity). We rated the strength of the evidence for this outcome as very low due to a high risk of bias (i.e. lack of blinding in one study) and serious imprecision (See <a href="./full#CD004610-tbl-0004">summary of findings Table 4</a>). </p> <p><b>Teicoplanin versus vancomycin</b> <br/> Sustained symptomatic cure was improved with teicoplanin compared to vancomycin, 87% (48/55) of patients who received teicoplanin achieved symptomatic cure compared to 73% (40/55) of patients who received vancomycin (RR 1.21, 95% CI 1.00 to 1.46; no heterogeneity; <a href="./references#CD004610-fig-0008" title="">Analysis 3.1</a>). Bacteriologic cure was reported by one small study. The quality of the evidence was very low in both cases due to a high risk of bias (i.e. lack of blinding) and serious imprecision due to small study sizes (See <a href="./full#CD004610-tbl-0003">summary of findings Table 3</a>). </p> <p><b>Fidaxomicin versus Vancomycin</b> <br/> Fidaxomicin was more effective than vancomycin for achieving symptomatic cure in two large studies. Seventy‐one per cent (407/572) of fidaxomicin patients achieved symptomatic cure compared to 61% (361/592) of vancomycin patients (RR 1.17, 1.07 to 1.27, <a href="./references#CD004610-fig-0012" title="">Analysis 5.1</a>; no heterogeneity). The quality of the evidence was rated as moderate due to high risk of bias (<a href="./full#CD004610-tbl-0003">summary of findings Table 3</a>) </p> <p>Interventions for which there was only a single, usually very small, included study, or in some cases two studies, are reported below. All of these comparisons are subject to very serious imprecision due to the small number of participants and events within the study population and in some cases high risk of bias or inconsistency issues as well, so the quality of evidence for these comparisons was either low or very low. </p> <p><b>Vancomycin versus placebo</b> <br/> In a very small study (n = 44) vancomycin was found to be superior to placebo for symptomatic cure (RR 9.0, 95% 1.24 to 65.16) and for bacteriologic cure (RR 10.0, 95% CI 1.4 to 71.62). We rated the overall quality of the evidence supporting these outcomes as very low due to serious imprecision and high risk of bias (<a href="./references#CD004610-bbs2-0009" title="KeighleyMR , BurdonDW , ArabiY , WilliamsJA , ThompsonH , YoungsD , et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. British Medical Journal1978;2(6153):1667‐9. ">Keighley 1978</a>). </p> <p><b>Rifaximin versus Vancomycin</b> <br/> In a very small study of 20 patients symptomatic cure was not found to be significantly different in those treated with Rifaximin compared to vancomycin (RR 0.9, 95% CI 0.69 to 1.18). We rated the quality of the evidence as very low due to high risk of bias and serious imprecision (<a href="./references#CD004610-bbs2-0002" title="BoeroM , BertiE , MorgandoA , VermeG . Treatment of pseudomembranous colitis: a randomized controlled trial with rifaximin vs vancomycin [Terapia della colite da Clostridium difficile: risultati di uno studio randomizzato aperto rifaximina vs. vancomicina]. Microbiologia Medica1990;5(2):74‐7. ">Boero 1990</a>). </p> <p><b>Fusidic acid versus vancomycin</b> <br/> No difference in symptomatic cure was found in a single small study comparing vancomycin to fusidic acid (<a href="./references#CD004610-bbs2-0019" title="WenischC , ParschalkB , HasenhundlM , HirschlAM , GraningerW . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases1996;22(5):813‐8. ">Wenisch 1996</a>). Seventy‐seven per cent (24/31) of patients who received vancomycin achieved symptomatic cure compared to 66% (19/29) of patients who received fusidic acid (RR 0.85, 95% CI 0.61 to 1.17). There was also in no difference in bacteriologic cure (RR 0.68, 95% CI 0.44 to 1.06). The quality of the evidence was rated as very low due to high risk of bias and serious imprecision). <a href="./references#CD004610-bbs2-0020" title="WulltM , OdenholtI . A double‐blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile‐associated diarrhoea. Journal of Antimicrobial Chemotherapy2004;54(1):211‐6. ">Wullt 2004</a> also studied this comparison in 131 patients but reported no recurrence data. Addition of <a href="./references#CD004610-bbs2-0020" title="WulltM , OdenholtI . A double‐blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile‐associated diarrhoea. Journal of Antimicrobial Chemotherapy2004;54(1):211‐6. ">Wullt 2004</a> to the analysis did not greatly change the results (RR 0.94, 95% CI 0.83 to 1.08) or the GRADE rating. </p> <p><b>Nitazoxanide versus vancomycin</b> <br/> Symptomatic cure was achieved in one small study (n = 49) almost equally with vancomycin and nitazoxanide. Sixty‐seven per cent (18/27) of vancomycin patients were cured compared to 73% (16/22) of patients who received nitazoxanide (RR 1.09, 95% CI 0.75 to 1.58). The quality of evidence was low due to serious imprecision (<a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a>). </p> <p><b>Metronidazole versus Nitazoxanide</b> <br/> A single small study found little difference in the efficacy of metronidazole and nitazoxanide in achieving symptomatic cure (RR 0.97, 95% CI 0.70 to 1.34). The quality of the evidence was very low due to high risk of bias (i.e. attrition) and serious imprecision (<a href="./references#CD004610-bbs2-0016" title="MusherDM , LoganN , HamillRJ , DupontHL , LentnekA , GuptaA , et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clinical Infectious Diseases2006;43(4):421‐7. ">Musher 2006</a>). </p> <p><b>Metronidazole versus Metronidazole and Rifampin</b> <br/> In a single small study (n = 39) there was little difference between metronidazole alone and metronidazole combined with rifampin in achieving symptomatic cure (RR 1.09, 95% CI 0.49 to 2.41). The quality of the evidence was very low due to high risk of bias and serious imprecision (<a href="./references#CD004610-bbs2-0010" title="LagrottereriaD , HolmesS , SmiejaM , SmaillF , LeeC . Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases2006;43(5):547‐52. ">Lagrotteria 2006</a>). </p> <p><b>Metronidazole versus Teicoplanin</b> <br/> In one small study (n = 59) teicoplanin was not significantly more effective than metronidazole in achieving symptomatic cure (RR 0.87, 95% CI 0.69 to 1.09). The quality of the evidence was very low due to high risk of bias (i.e. lack of blinding and failure to exclude other pathogens) and serious imprecision (<a href="./references#CD004610-bbs2-0019" title="WenischC , ParschalkB , HasenhundlM , HirschlAM , GraningerW . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases1996;22(5):813‐8. ">Wenisch 1996</a>). </p> <p><b>Metronidazole versus Fusidic Acid</b> <br/> Metronidazole was no more effective than fusidic acid for achieving symptomatic cure in two small studies (RR 1.00, 95% CI 0.78 to 1.30). Similar results were seen in these two small studies for bacteriologic cure (RR 1.02, 95% CI 0.83 to 1.25; no heterogeneity). The quality of the evidence was very low due to high risk of bias (i.e. lack of blinding and attrition) and serious imprecision (<a href="./references#CD004610-bbs2-0019" title="WenischC , ParschalkB , HasenhundlM , HirschlAM , GraningerW . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases1996;22(5):813‐8. ">Wenisch 1996</a>; <a href="./references#CD004610-bbs2-0020" title="WulltM , OdenholtI . A double‐blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile‐associated diarrhoea. Journal of Antimicrobial Chemotherapy2004;54(1):211‐6. ">Wullt 2004</a>). </p> <p><b>Teicoplanin versus Fusidic Acid</b> <br/> In one small study (n = 57) teicoplanin was more effective then fusidic acid for achieving symptomatic cure (RR 1.36, 95% CI 1.02 to 1.83), and bacteriologic cure (RR 1.73, 95% CI 1.19 to 2.51). The quality of evidence was very low due to high risk of bias (i.e. no blinding and failure to rule out other enteric pathogens) and serious imprecision (<a href="./references#CD004610-bbs2-0019" title="WenischC , ParschalkB , HasenhundlM , HirschlAM , GraningerW . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases1996;22(5):813‐8. ">Wenisch 1996</a>). </p> <p><b>Dose Finding</b> <br/> One small study (n = 56, <a href="./references#CD004610-bbs2-0006" title="FeketyR , SilvaJ , KauffmanC , BuggyB , DeeryHG . Treatment of antibiotic‐associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. American Journal of Medicine1989;86(1):15‐9. ">Fekety 1989</a>), found no difference in symptomatic cure between high and low dose regimens of vancomycin (RR 0.95, 95% CI 0.65 to 1.38) in one small study. For fidaxomicin, also known as Opt‐80 (n = 48, <a href="./references#CD004610-bbs2-0012" title="LouieT , MillerM , DonskeyC , MullaneK , GoldsteinEJ . Clinical outcomes, safety and pharmacokinetics of OPT‐80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2009;53(1):223‐8. ">Louie 2009</a>), it appeared that the higher (200 mg) dose was more effective than low dose for symptomatic cure (RR 1.26, 95% CI 1.03 to 1.54). Both studies were very small and also had a high risk of bias (i.e. attrition, lack of blinding), and serious imprecision. The quality of the evidence was very low for both comparisons. </p> <p><b>Dose Timing</b> <br/> The dose of teicoplanin was maintained constant but administered in varying intervals in this small single study (n = 92). The dose was administered either twice or four times a day. There was no difference in symptomatic cure between doses administered twice or four times daily (RR 0.57, 95% CI 0.27 to 1.20). The study was terminated prematurely due to a higher than expected failure rate in the twice daily group. The quality of evidence in the study was very low due to high risk of bias (i.e. attrition) and serious imprecision (<a href="./references#CD004610-bbs2-0001" title="Anonymous . Treatment of Clostridium difficile‐associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group. Scandinavian Journal of Infectious Diseases1994;26(3):309‐16. ">Anonymous 1994</a>). </p> <p><b>Rifaximin to diminish relapse risk</b> <br/> After primary therapy of CDI with either metronidazole or vancomycin, rifaximin was found in one study to be insignificantly more effective than placebo for avoiding relapse (RR 0.61, 95% CI 0.36 to 1.02). The quality of evidence was low due to high risk of bias and imprecision (<a href="./references#CD004610-bbs2-0007" title="GareyKW , GhantojiSS , ShahDN , HabibM , AroraV , JiangZD , et al. A randomized, double‐blind, placebo‐controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy2011;66(12):2850‐5. ">Garey 2011</a>). </p> <p><b>Cadazolid versus Vancomycin</b> <br/> In this small single study , three different doses of a new antibiotic, cadazolid, were compared to vancomycin in 82 patients. The results for all three doses were very similar and so we combined the dose groups as a single exposure to vancomycin, also with very similar effect (RR 1.11, 95% CI 0.50 to 2.00). The quality of the evidence was moderate due to imprecision (<a href="./references#CD004610-bbs2-0014" title="LouieT , NordCE , TalbotGH , WilcoxM , GerdingDN , BuitragoM , et al. Multicenter, double‐blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2015;59(10):6266‐73. ">Louie 2015</a>). </p> <p><b>LFF517 versus vancomycin</b> <br/> This new antibiotic, as yet without a name, was compared to vancomycin in 76 randomised patients of whom 32 did not finish the study (RR 0.87, 95% CI 0.49 to 1.57). The quality of the evidence was very low due to high risk of bias attrition and serious imprecision (<a href="./references#CD004610-bbs2-0015" title="MullaneK , LeeC , BresslerA , BuitragoM , WeissK , DabovicK , et al. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrobial Agents and Chemotherapy2015;59(3):1435‐40. ">Mullane 2015</a>). </p> <p><b>Surotomycin versus vancomycin</b> <br/> One study (n = 209) compared two doses of surotomycin, a new antibiotic, to vancomycin (<a href="./references#CD004610-bbs2-0011" title="LeeCH , PatinoH , StevensC , RegeS , ChesnelL , LouieT , et al. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double‐blind, non‐inferiority, multicentre trial. Journal of Antimicrobial Chemotherapy2016;71(10):2964‐71. ">Lee 2016a</a>). The results of the two doses were almost identical so these groups were combined in comparison to vancomycin. Surotomycin was marginally more effective than vancomycin for maintaining a sustained clinical cure (RR 1.22, 95% CI 0.95 to 1.56). The quality of evidence was moderate due to imprecision. </p> <p>Older guidelines discuss treatment of unresponsive disease with an increased dose of vancomycin 500 mg four times daily, intravenous metronidazole 500 mg three times daily and rifampicin 300 mg twice daily. However, this regimen was shown to have no clinical benefit in primary CDI (<a href="./references#CD004610-bbs2-0007" title="GareyKW , GhantojiSS , ShahDN , HabibM , AroraV , JiangZD , et al. A randomized, double‐blind, placebo‐controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy2011;66(12):2850‐5. ">Garey 2011</a>; <a href="./references#CD004610-bbs2-0010" title="LagrottereriaD , HolmesS , SmiejaM , SmaillF , LeeC . Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases2006;43(5):547‐52. ">Lagrotteria 2006</a>). The criteria defining severity stratification have differed across the studies included in this review (<a href="./references#CD004610-bbs2-0055" title="BauerMP , KuijperEJ , vanDisselJT . European society of clinical microbiology and infectious diseases (ESCMID): treatment guidance for Clostridium difficile infection (CDI). Clinical Microbiology and Infection2009;15(12):1067‐79. ">Bauer 2009</a>; <a href="./references#CD004610-bbs2-0058" title="CohenSH , GerdingDN , JohnsonS , KellyCP , LooVG , McDonaldLC , et al. Clinical practice guidelines for clostridium difficile infection in adults: 2010 update for the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology2010;31(5):431‐55. ">Cohen 2010</a>; <a href="./references#CD004610-bbs2-0070" title="Health Protection Agency. Deaths involving Clostridium difficile or MRSA, Wales: 2015. www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsinvolvingclostridiumdifficilewales/2015 (accessed 26 January 2017). ">HPA 2016</a><a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a>; <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a>). Lactate &gt; 5 is perhaps the most valid marker of extreme disease severity, but it is associated with a 75% operative mortality. Therefore an earlier marker and proven therapy would be of more use (<a href="./references#CD004610-bbs2-0058" title="CohenSH , GerdingDN , JohnsonS , KellyCP , LooVG , McDonaldLC , et al. Clinical practice guidelines for clostridium difficile infection in adults: 2010 update for the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology2010;31(5):431‐55. ">Cohen 2010</a>). No randomised studies address this issue. </p> <p>The patients with relapse of diarrhoea after treatment were re‐treated in various ways. <a href="./references#CD004610-bbs2-0005" title="DudleyMN , McLaughlinJC , CarringtonG , FrickJ , NightingaleCH , QuintilianiR . Oral bacitracin vs vancomycin therapy for Clostridium difficile‐induced diarrhea. A randomized double‐blind trial. Archives of Internal Medicine1986;146(6):1101‐4. ">Dudley 1986</a> re‐treated with the same antibiotic and <a href="./references#CD004610-bbs2-0021" title="YoungGP , WardPB , BayleyN , GordonD , HigginsG , TrapaniJA , et al. Antibiotic‐associated colitis due to Clostridium difficile: double‐blind comparison of vancomycin with bacitracin. Gastroenterology1985;89(5):1038‐45. ">Young 1985</a> re‐treated with the antibiotic from the other arm of the study. <a href="./references#CD004610-bbs2-0004" title="DeLallaF , NicolinR , RinaldiE , ScarpelliniP , RigoliR , ManfrinV , et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile‐associated diarrhea. Antimicrobial Agents and Chemotherapy1992;36(10):2192‐6. ">De Lalla 1992</a> stated that the patients with relapse were re‐treated, but analysed the results in aggregate, making it impossible to compare the antibiotics for efficacy. The <a href="./references#CD004610-bbs2-0006" title="FeketyR , SilvaJ , KauffmanC , BuggyB , DeeryHG . Treatment of antibiotic‐associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. American Journal of Medicine1989;86(1):15‐9. ">Fekety 1989</a> vancomycin dose‐finding study re‐treated all nine relapses with vancomycin and subsequently cured these patients. <a href="./references#CD004610-bbs2-0019" title="WenischC , ParschalkB , HasenhundlM , HirschlAM , GraningerW . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases1996;22(5):813‐8. ">Wenisch 1996</a> treated recurrent disease with teicoplanin with a reported a 100% cure rate. <a href="./references#CD004610-bbs2-0012" title="LouieT , MillerM , DonskeyC , MullaneK , GoldsteinEJ . Clinical outcomes, safety and pharmacokinetics of OPT‐80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2009;53(1):223‐8. ">Louie 2009</a> re‐treated with either metronidazole or vancomycin, but did not report on the success of this treatment. The remaining studies did not report on the re‐treatment of relapses. As in the previous paragraph, the focus of randomised trials has been the prevention of recurrence and not its treatment. <a href="./references#CD004610-bbs2-0008" title="JohnsonS , LouieTJ , GerdingDN , CornelyOA , Chasan‐TaberS , FittsD , et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases2014;59(3):345‐54. ">Johnson 2014</a> did enroll patients with recurrent disease as well as primary disease, but there is no mention in the paper that the recurrent patients were randomised separately so that the reporting of outcome of primary versus recurrent patients is once again a post hoc subgroup analysis (<a href="./references#CD004610-bbs2-0049" title="AssmannSF , PocockSJ , EnosLE , KastenLE . Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet2000;355(9209):1064‐9. ">Assmann 2000</a>). </p> <p><b>Secondary outcome: Death</b> <br/> The secondary outcome measured in this review, death, occurred infrequently in all of the studies. There were 140 deaths among the patients in the included studies. All of the reported deaths were described by the study authors as being due to the underlying morbidity that preceded CDI rather than the antibiotics used to treat CDI (<a href="#CD004610-tbl-0005">Table 1</a>). Although most of these patients had severe diseases prior to the diagnosis of CDI, it seems plausible that the CDI or antibiotic therapy could have contributed to their deaths. <a href="./references#CD004610-bbs2-0005" title="DudleyMN , McLaughlinJC , CarringtonG , FrickJ , NightingaleCH , QuintilianiR . Oral bacitracin vs vancomycin therapy for Clostridium difficile‐induced diarrhea. A randomized double‐blind trial. Archives of Internal Medicine1986;146(6):1101‐4. ">Dudley 1986</a> reported one death and one partial colectomy after failed treatment of CDI with bacitracin. Both patients were crossed‐over to vancomycin before their adverse outcome, with the first patient improving prior to his death, and the second patient continuing to have CDI. <a href="./references#CD004610-bbs2-0006" title="FeketyR , SilvaJ , KauffmanC , BuggyB , DeeryHG . Treatment of antibiotic‐associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. American Journal of Medicine1989;86(1):15‐9. ">Fekety 1989</a> reported one death in each of the two vancomycin treatment arms. The Swedish CDI study reported one death in the two times per day teicoplanin group, but the authors did not specify if it was part of the CDI sub‐section of the study or part of the general dosage‐finding portion of the study (<a href="./references#CD004610-bbs2-0001" title="Anonymous . Treatment of Clostridium difficile‐associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group. Scandinavian Journal of Infectious Diseases1994;26(3):309‐16. ">Anonymous 1994</a>). <a href="./references#CD004610-bbs2-0018" title="TeasleyDG , GerdingDN , OlsonMM , PetersonLR , GebhardRL , SchwartzMJ , et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile‐associated diarrhoea and colitis. Lancet1983;2(8358):1043‐6. ">Teasley 1983</a> had three deaths in the whole study, including two deaths in the vancomycin treatment arm. The authors attributed all three deaths to underlying illness and not to CDAD or the antibiotic therapy, a common claim in other studies as well. <a href="./references#CD004610-bbs2-0004" title="DeLallaF , NicolinR , RinaldiE , ScarpelliniP , RigoliR , ManfrinV , et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile‐associated diarrhea. Antimicrobial Agents and Chemotherapy1992;36(10):2192‐6. ">De Lalla 1992</a> reported two deaths and <a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a> reported one death. Both studies did not specify the treatment group and attributed the deaths to the patients' underlying disease. <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> reported eight deaths, four in each treatment group, but did not comment on the cause of mortality. <a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a> and <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a> reported 74 deaths in their two large studies, all felt to be due to the patient's primary disease and not associated with either antibiotic being investigated. <a href="./references#CD004610-bbs2-0008" title="JohnsonS , LouieTJ , GerdingDN , CornelyOA , Chasan‐TaberS , FittsD , et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases2014;59(3):345‐54. ">Johnson 2014</a> reported 23 and 16 deaths in the metronidazole and vancomycin groups respectively again attributed to the patients' underlying comorbidity. There were two deaths in <a href="./references#CD004610-bbs2-0014" title="LouieT , NordCE , TalbotGH , WilcoxM , GerdingDN , BuitragoM , et al. Multicenter, double‐blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2015;59(10):6266‐73. ">Louie 2015</a>. <a href="./references#CD004610-bbs2-0011" title="LeeCH , PatinoH , StevensC , RegeS , ChesnelL , LouieT , et al. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double‐blind, non‐inferiority, multicentre trial. Journal of Antimicrobial Chemotherapy2016;71(10):2964‐71. ">Lee 2016a</a> reported four deaths, two in each of the two treatment groups, all attributed to underlying disease. </p> <div class="table" id="CD004610-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Deaths</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Harms due to</b> </p> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Attrition%</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Stratified by</b> </p> <p><b>Severity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0001" title="Anonymous . Treatment of Clostridium difficile‐associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group. Scandinavian Journal of Infectious Diseases1994;26(3):309‐16. ">Anonymous 1994</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>joint pain</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;10%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0002" title="BoeroM , BertiE , MorgandoA , VermeG . Treatment of pseudomembranous colitis: a randomized controlled trial with rifaximin vs vancomycin [Terapia della colite da Clostridium difficile: risultati di uno studio randomizzato aperto rifaximina vs. vancomicina]. Microbiologia Medica1990;5(2):74‐7. ">Boero 1990</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>535</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 Fid</p> <p>17 Van</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>none</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.9%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes post</p> <p>randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0004" title="DeLallaF , NicolinR , RinaldiE , ScarpelliniP , RigoliR , ManfrinV , et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile‐associated diarrhea. Antimicrobial Agents and Chemotherapy1992;36(10):2192‐6. ">De Lalla 1992</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0005" title="DudleyMN , McLaughlinJC , CarringtonG , FrickJ , NightingaleCH , QuintilianiR . Oral bacitracin vs vancomycin therapy for Clostridium difficile‐induced diarrhea. A randomized double‐blind trial. Archives of Internal Medicine1986;146(6):1101‐4. ">Dudley 1986</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0006" title="FeketyR , SilvaJ , KauffmanC , BuggyB , DeeryHG . Treatment of antibiotic‐associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. American Journal of Medicine1989;86(1):15‐9. ">Fekety 1989</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0007" title="GareyKW , GhantojiSS , ShahDN , HabibM , AroraV , JiangZD , et al. A randomized, double‐blind, placebo‐controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy2011;66(12):2850‐5. ">Garey 2011</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>skin rash</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0008" title="JohnsonS , LouieTJ , GerdingDN , CornelyOA , Chasan‐TaberS , FittsD , et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases2014;59(3):345‐54. ">Johnson 2014</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1118</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 Met</p> <p>16 Van</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>none</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes post</p> <p>randonisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0010" title="LagrottereriaD , HolmesS , SmiejaM , SmaillF , LeeC . Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases2006;43(5):547‐52. ">Lagrotteria 2006</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0011" title="LeeCH , PatinoH , StevensC , RegeS , ChesnelL , LouieT , et al. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double‐blind, non‐inferiority, multicentre trial. Journal of Antimicrobial Chemotherapy2016;71(10):2964‐71. ">Lee 2016a</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>209</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0012" title="LouieT , MillerM , DonskeyC , MullaneK , GoldsteinEJ . Clinical outcomes, safety and pharmacokinetics of OPT‐80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2009;53(1):223‐8. ">Louie 2009</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>629</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 Fid</p> <p>21 Van</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>elevated</p> <p>liver enzymes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.2%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes post</p> <p>randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0014" title="LouieT , NordCE , TalbotGH , WilcoxM , GerdingDN , BuitragoM , et al. Multicenter, double‐blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2015;59(10):6266‐73. ">Louie 2015</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0015" title="MullaneK , LeeC , BresslerA , BuitragoM , WeissK , DabovicK , et al. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrobial Agents and Chemotherapy2015;59(3):1435‐40. ">Mullane 2015</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0016" title="MusherDM , LoganN , HamillRJ , DupontHL , LentnekA , GuptaA , et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clinical Infectious Diseases2006;43(4):421‐7. ">Musher 2006</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes post</p> <p> randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0018" title="TeasleyDG , GerdingDN , OlsonMM , PetersonLR , GebhardRL , SchwartzMJ , et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile‐associated diarrhoea and colitis. Lancet1983;2(8358):1043‐6. ">Teasley 1983</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0019" title="WenischC , ParschalkB , HasenhundlM , HirschlAM , GraningerW . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases1996;22(5):813‐8. ">Wenisch 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>126</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0020" title="WulltM , OdenholtI . A double‐blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile‐associated diarrhoea. Journal of Antimicrobial Chemotherapy2004;54(1):211‐6. ">Wullt 2004</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0021" title="YoungGP , WardPB , BayleyN , GordonD , HigginsG , TrapaniJA , et al. Antibiotic‐associated colitis due to Clostridium difficile: double‐blind comparison of vancomycin with bacitracin. Gastroenterology1985;89(5):1038‐45. ">Young 1985</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>172</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes but</p> <p>uncertain</p> <p>when</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TOTAL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>NR: None reported</p> </div> </div> <p><b>Drug‐related adverse events (DRAE)</b> <br/> DRAEs were reported very differently in the included studies. It was reported that there were none (or not reported) in six studies (<a href="./references#CD004610-bbs2-0004" title="DeLallaF , NicolinR , RinaldiE , ScarpelliniP , RigoliR , ManfrinV , et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile‐associated diarrhea. Antimicrobial Agents and Chemotherapy1992;36(10):2192‐6. ">De Lalla 1992</a>; <a href="./references#CD004610-bbs2-0005" title="DudleyMN , McLaughlinJC , CarringtonG , FrickJ , NightingaleCH , QuintilianiR . Oral bacitracin vs vancomycin therapy for Clostridium difficile‐induced diarrhea. A randomized double‐blind trial. Archives of Internal Medicine1986;146(6):1101‐4. ">Dudley 1986;</a><a href="./references#CD004610-bbs2-0006" title="FeketyR , SilvaJ , KauffmanC , BuggyB , DeeryHG . Treatment of antibiotic‐associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. American Journal of Medicine1989;86(1):15‐9. ">Fekety 1989;</a><a href="./references#CD004610-bbs2-0018" title="TeasleyDG , GerdingDN , OlsonMM , PetersonLR , GebhardRL , SchwartzMJ , et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile‐associated diarrhoea and colitis. Lancet1983;2(8358):1043‐6. ">Teasley 1983;</a><a href="./references#CD004610-bbs2-0021" title="YoungGP , WardPB , BayleyN , GordonD , HigginsG , TrapaniJA , et al. Antibiotic‐associated colitis due to Clostridium difficile: double‐blind comparison of vancomycin with bacitracin. Gastroenterology1985;89(5):1038‐45. ">Young 1985;</a><a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a>). At the opposite end of the spectrum, quite remarkably high incidences of what was described as therapy emergent adverse events (TEAE) were reported by <a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a> (75% with fidaxomicin and 71.5% for vancomycin, 26.5% and 22.3% described as serious), <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a> (62.3%, 25% serious for fidaxomicin, 60.4%, 24.1% serious for vancomycin), and <a href="./references#CD004610-bbs2-0008" title="JohnsonS , LouieTJ , GerdingDN , CornelyOA , Chasan‐TaberS , FittsD , et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases2014;59(3):345‐54. ">Johnson 2014</a> (35.3% vancomycin, 31.2% metronidazole). All three studies reported that around 1% of these TEAEs were due to study medications. All the other studies, attributed adverse events to the many serious co‐morbidities these patients had that gave rise to the CDI. Anecdotally reported DRAEs included pruritis, skin rash (<a href="./references#CD004610-bbs2-0007" title="GareyKW , GhantojiSS , ShahDN , HabibM , AroraV , JiangZD , et al. A randomized, double‐blind, placebo‐controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy2011;66(12):2850‐5. ">Garey 2011</a>), joint pain (<a href="./references#CD004610-bbs2-0001" title="Anonymous . Treatment of Clostridium difficile‐associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group. Scandinavian Journal of Infectious Diseases1994;26(3):309‐16. ">Anonymous 1994</a>), nausea (<a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a>) and vomiting (<a href="./references#CD004610-bbs2-0019" title="WenischC , ParschalkB , HasenhundlM , HirschlAM , GraningerW . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases1996;22(5):813‐8. ">Wenisch 1996</a>), and elevation of liver enzymes (<a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a>). <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> reported two adverse events that were clearly drug‐related, one patient in each treatment group had nausea and were switched to the other drug and completed therapy (as a crossover). None of the TEAEs are presented in a way that allows quantification of DRAE across studies in a summary of findings table. Most of the adverse events in <a href="./references#CD004610-bbs2-0011" title="LeeCH , PatinoH , StevensC , RegeS , ChesnelL , LouieT , et al. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double‐blind, non‐inferiority, multicentre trial. Journal of Antimicrobial Chemotherapy2016;71(10):2964‐71. ">Lee 2016a</a> were indistinguishable from symptoms of CDI. Five patients ceased taking the medications due to unspecified adverse events (<a href="./references#CD004610-bbs2-0011" title="LeeCH , PatinoH , StevensC , RegeS , ChesnelL , LouieT , et al. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double‐blind, non‐inferiority, multicentre trial. Journal of Antimicrobial Chemotherapy2016;71(10):2964‐71. ">Lee 2016a</a>). </p> <p><b>Cost</b> <br/> Two studies quantified the cost of treatment (<a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a>; <a href="./references#CD004610-bbs2-0019" title="WenischC , ParschalkB , HasenhundlM , HirschlAM , GraningerW . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases1996;22(5):813‐8. ">Wenisch 1996</a>). <a href="./references#CD004610-bbs2-0019" title="WenischC , ParschalkB , HasenhundlM , HirschlAM , GraningerW . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases1996;22(5):813‐8. ">Wenisch 1996</a> compared four different antibiotics. The cost data calculated at the time of the initial publication of this review for a course of treatment were: Metronidazole USD 35; Fusidic acid USD 287; Vancomycin USD 2030; and Teicoplanin USD 3430 (<a href="./references#CD004610-bbs2-0095" title="BrickerE , GargR , NelsonR , LozaA , NovakT , HansenJ . Antibiotic treatment for Clostridium difficile‐associated diarrhea in adults. Cochrane Database of Systematic Reviews2005, Issue 1. [DOI: 10.1002/14651858.CD004610.pub2] ">Bricker 2005</a>). <a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a> compared two antibiotics. The cost data were as follows: Vancomycin USD 618 and Nitazoxanide USD 316 (<a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a>). </p> <p>More recent cost data (July 2016) for a 10 day course of treatment includes Metronidazole #20 500 mg USD 13 (Health Warehouse); Vancomycin 125 mg USD 1779 (Walgreens for 56 tablets); Fidaxomicin #20 200 mg: USD 3453.83 or more (Optimer Pharmaceuticals) and Teicoplanin approximately USD 83.67 (GBP 71.40, British National Formulary). </p> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004610-sec-0072" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004610-sec-0072"></div> <p>Perhaps the biggest change for this update when compared to previous versions of this review is the change in outcome assessment. Recurrence rates have been reported to be high after initial resolution of CDI symptoms and assays, topping 20% (<a href="./references#CD004610-bbs2-0094" title="VardakasKZ , PolyzosKA , PatouniK , RafailidisPI , SamonisG , FalagasME . Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. International Journal of Antimicrobial Agents2012;40(1):1‐8. ">Vardakas 2012</a>). There has been increasing emphasis on addressing the risk of recurrence of CDI as part of the primary therapy, with the desired outcome being a sustained symptomatic cure and bacteriologic cure (<a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a>; <a href="./references#CD004610-bbs2-0007" title="GareyKW , GhantojiSS , ShahDN , HabibM , AroraV , JiangZD , et al. A randomized, double‐blind, placebo‐controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy2011;66(12):2850‐5. ">Garey 2011</a>; <a href="./references#CD004610-bbs2-0071" title="JohnsonS , GerdingDN , LouieTJ , RuizNM , GorbachSL . Sustained clinical response as an endpoint in treatment trials of Clostridium difficile‐associated diarrhea. Antimicrobial Agents and Chemotherapy2012;56(8):4043‐5. ">Johnson 2012</a>; <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a>). The previous set of outcomes for this systematic review have been condensed to: sustained symptomatic and bacteriologic cure, along with adverse events of the intervention and death. This should not just instruct how best to treat CDI patients but also provide the optimal protection for other hospitalised patients. In addition the number of outcomes assessed compared to previous versions is decreased by more than 50%, thus addressing the issue of multiplicity (<a href="./references#CD004610-bbs2-0087" title="SedgwickP . Multiple hypothesis testing and Bonferroni's correction. BMJ (Clinical research ed.)2014;349:g6284. ">Sedgwick 2014</a>). </p> <section id="CD004610-sec-0073"> <h3 class="title" id="CD004610-sec-0073">Summary of main results</h3> <p>The main results of this update have changed considerably since 2011. Moderate quality evidence suggests that vancomycin is more effective than metronidazole for achieving symptomatic cure, but the evidence is less supportive for bacteriologic cure (very low quality evidence; See <a href="./references#CD004610-fig-0004" title="">Analysis 1.1</a>, <a href="./references#CD004610-fig-0005" title="">Analysis 1.2</a>, <a href="./references#CD004610-fig-0006" title="">Analysis 1.3</a>, <a href="./full#CD004610-tbl-0001">summary of findings Table for the main comparison</a>). Moderate quality evidence suggests that fidaxomicin is superior to vancomycin for achieving symptomatic cure with no direct data on bacteriologic cure (See <a href="./references#CD004610-fig-0012" title="">Analysis 5.1</a>, <a href="./full#CD004610-tbl-0003">summary of findings Table 3</a>). Very low quality evidence from older smaller studies suggests that teicoplanin is a potentially effective drug compared to vancomycin or metronidazole (See <a href="./references#CD004610-fig-0008" title="">Analysis 3.1</a>, <a href="./full#CD004610-tbl-0002">summary of findings Table 2</a>). Surotomycin was marginally superior to vancomycin (Analysis 6.1) based on a single study (n = 209). The use of the remaining antibiotics for treatment of CDI including bacitracin, fusidic acid, nitazoxanide, cadazolid, LFF571, rifaximin and rifampin was not supported by the evidence. The evidence supporting a specific therapy for bacteriologic cure is less conclusive, principally because the more recent and largest studies have not reported data that would allow assessment of bacteriologic cure (<a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a>; <a href="./references#CD004610-bbs2-0008" title="JohnsonS , LouieTJ , GerdingDN , CornelyOA , Chasan‐TaberS , FittsD , et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases2014;59(3):345‐54. ">Johnson 2014</a>; <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a>). Rifaximin given after a course of vancomycin of metronidazole may diminish the likelihood of recurrent CDI (<a href="./references#CD004610-bbs2-0007" title="GareyKW , GhantojiSS , ShahDN , HabibM , AroraV , JiangZD , et al. A randomized, double‐blind, placebo‐controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy2011;66(12):2850‐5. ">Garey 2011</a>). </p> </section> <section id="CD004610-sec-0074"> <h3 class="title" id="CD004610-sec-0074">Overall completeness and applicability of evidence</h3> <p>The available evidence applies directly to the goals of this review: to assess the efficacy of antibiotic therapy for CDI. The results of this review are applicable to patients with mild CDI who can tolerate oral antibiotics. All of the included studies excluded patients with severe CDI. </p> </section> <section id="CD004610-sec-0075"> <h3 class="title" id="CD004610-sec-0075">Quality of the evidence</h3> <p>The only placebo‐controlled study of primary CDI was <a href="./references#CD004610-bbs2-0009" title="KeighleyMR , BurdonDW , ArabiY , WilliamsJA , ThompsonH , YoungsD , et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. British Medical Journal1978;2(6153):1667‐9. ">Keighley 1978</a>. This is important since it could have provided evidence on how likely it is that CDI would spontaneously resolve. <a href="./references#CD004610-bbs2-0009" title="KeighleyMR , BurdonDW , ArabiY , WilliamsJA , ThompsonH , YoungsD , et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. British Medical Journal1978;2(6153):1667‐9. ">Keighley 1978</a> assessed the efficacy of oral vancomycin 125 mg taken four times a day for five days compared to placebo for the treatment of pseudomembranous colitis. All patients were recruited from a surgical ward and blinded during the five day treatment period. It is unclear from the study report whether the outcome assessor was blinded or not. Broad inclusion criteria were used. Any patient with postoperative diarrhoea was recruited. This led to the randomisation of patients with postoperative diarrhoea not related to <i>C. difficile</i> . The only exclusion criterion was a previous history of pseudomembranous colitis. The study not only divided patients by their treatment regimen, but also divided patients into three groups based on stool analysis results. Group one had stool that was culture positive for <i>C. difficile</i> and positive for <i>C. difficile</i> cytotoxin. Group two had stool that was culture positive for <i>C. difficile</i> only. Group three had stool that was culture negative and negative for cytotoxin.<br/> <br/> <a href="./references#CD004610-bbs2-0009" title="KeighleyMR , BurdonDW , ArabiY , WilliamsJA , ThompsonH , YoungsD , et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. British Medical Journal1978;2(6153):1667‐9. ">Keighley 1978</a> reported that only 21 of 44 randomised patients had some evidence of <i>C. difficile</i> infection. Of these patients 16 were toxin positive and 5 were culture positive. Twelve of these patients were in the vancomycin group and nine were in the placebo group. <a href="./references#CD004610-bbs2-0009" title="KeighleyMR , BurdonDW , ArabiY , WilliamsJA , ThompsonH , YoungsD , et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. British Medical Journal1978;2(6153):1667‐9. ">Keighley 1978</a> defined clinical response measured by stool frequency as resolution. Clinical response was higher in patients who received vancomycin in groups one and two, but response was not affected by treatment in group three. <a href="./references#CD004610-bbs2-0009" title="KeighleyMR , BurdonDW , ArabiY , WilliamsJA , ThompsonH , YoungsD , et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. British Medical Journal1978;2(6153):1667‐9. ">Keighley 1978</a> describes the numbers of patients taking vancomycin or placebo in whom stool converted to negative for C. difficile strain, negative for fecal cytotoxin and negative for histological evidence of pseudomembranous colitis. There are several major bias concerns with the <a href="./references#CD004610-bbs2-0009" title="KeighleyMR , BurdonDW , ArabiY , WilliamsJA , ThompsonH , YoungsD , et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. British Medical Journal1978;2(6153):1667‐9. ">Keighley 1978</a> study. The number of patients was small, and follow‐up was inadequate. During the convalescence period, there were specimens that were either not taken or mislaid. Two‐thirds of the patients in the vancomycin group fell into this category. Follow‐up conclusions were based on only four patients from the total of 12 patients with evidence of <i>C. difficile</i> infection that received vancomycin. </p> <p>As mentioned above, <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> has had a great influence because of its stratification of outcome assessment by disease severity. Because of this, potential issues bear special attention. Despite the publication date, recruitment for this study ended in 2002, before the 027 strain of <i>C. difficile</i> reached the Chicago area, where the <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> study was conducted, and the severity of disease seen in this mutation had not yet been witnessed. Yet, in spite of excluding the sickest patients with CDI from the study, eight participants died within five days of the onset of therapy and were excluded from further analysis rather than being regarded as treatment failures. Randomisation also occurred before the diagnosis of <i>C. difficile</i> was established, and 14 randomised subjects were subsequently found to be <i>C. difficile</i> negative and excluded from analysis. If randomisation, was done prior to severity stratification, this may not sufficiently validate this concept of severity stratification in antibiotic choice as described by <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a>. </p> <p>Two very large and for the most part well conducted studies of identical design compared fidaxomicin and vancomycin (<a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a>; <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a>). The quality issues in these studies are fairly minor compared to the above studies. The dropout rate was only 5%. These studies utilized a non‐inferiority design. The necessity of doing this rather than a standard analysis was not discussed, although the design itself has been a frequent topic of discussion elsewhere (<a href="./references#CD004610-bbs2-0063" title="GarattiniS , BerteleV . Non‐inferiority trials are unethical because they disregard patients' interests. Lancet2007;370:1875‐6. ">Garattini 2007</a>; <a href="./references#CD004610-bbs2-0066" title="GotzscheP . Lessons from and cautions about noninferiority and equivalence randomized trials. JAMA2006;295(10):1172‐4. ">Gotzsche 2006</a>; <a href="./references#CD004610-bbs2-0088" title="SoonawalaD , MiddelbergRA , EggerM , VandenbrouckeJP , DekkersOM . Efficacy of experimental treatments compared with standard treatments in non‐inferiority trials: a meta‐analysis of randomized controlled trials.. International Journal of Epidemiology2010;39(6):1567‐81. ">Soonawala 2010</a>). An intention‐to‐treat analysis (ITT) was not reported in either publication, rather a 'modified intention‐to‐treat' which excluded a number of dropouts and a per protocol analysis, excluding even more participants were reported. Again the purpose of this was not discussed, and curious insofar as including the dropouts as treatment failures in a standard ITT analysis demonstrates the superiority of fadixamicin over vancomycin (<a href="./references#CD004610-fig-0012" title="">Analysis 5.1</a>). The studies were both funded by Optimer Incorporated and the <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a> manuscript was written by a part time employee of the company. </p> <p>The most recent added studies (<a href="./references#CD004610-bbs2-0014" title="LouieT , NordCE , TalbotGH , WilcoxM , GerdingDN , BuitragoM , et al. Multicenter, double‐blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2015;59(10):6266‐73. ">Louie 2015</a>; <a href="./references#CD004610-bbs2-0015" title="MullaneK , LeeC , BresslerA , BuitragoM , WeissK , DabovicK , et al. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrobial Agents and Chemotherapy2015;59(3):1435‐40. ">Mullane 2015</a>) are small and, like the previous two studies, theses studies also do not present results as a pure ITT analysis but a modified ITT or per protocol fashion. In this review, we conducted all analyses using the original number of patients randomised to each group as the denominator. </p> </section> <section id="CD004610-sec-0076"> <h3 class="title" id="CD004610-sec-0076">Potential biases in the review process</h3> <p>We believe that our changes in outcome assessment reduce the risk of bias in the review process. The results of this review are now more clinically realistic, and are now less subject to multiplicity (<a href="./references#CD004610-bbs2-0087" title="SedgwickP . Multiple hypothesis testing and Bonferroni's correction. BMJ (Clinical research ed.)2014;349:g6284. ">Sedgwick 2014</a>). </p> </section> <section id="CD004610-sec-0077"> <h3 class="title" id="CD004610-sec-0077">Agreements and disagreements with other studies or reviews</h3> <p><a href="./references#CD004610-bbs2-0056" title="BisharaJ , WattadM , PaulM . Vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases2007;45(12):1646‐7. ">Bishara 2007</a> found no statistically significant difference in symptomatic cure between metronidazole and vancomycin in a pooled analysis of three studies (RR 0.93; 95% CI 0.80 to 1.09) treating exclusions, deaths and relapses as treatment failures. This result is similar to the pooled analysis reported in this review prior to the inclusion of <a href="./references#CD004610-bbs2-0008" title="JohnsonS , LouieTJ , GerdingDN , CornelyOA , Chasan‐TaberS , FittsD , et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases2014;59(3):345‐54. ">Johnson 2014</a>. In a very heterogenous systematic review that included retrospective studies and prospective cohorts as well as RCTs, and non‐antibiotic therapies as well, <a href="./references#CD004610-bbs2-0094" title="VardakasKZ , PolyzosKA , PatouniK , RafailidisPI , SamonisG , FalagasME . Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. International Journal of Antimicrobial Agents2012;40(1):1‐8. ">Vardakas 2012</a> also found very similar results when comparing metronidazole to vancomycin for both initial symptomatic response and recurrence risk. <a href="./references#CD004610-bbs2-0060" title="DrekonjaDM , ButlerM , MacDonaldR , BlissD , FiliceGA , RectorTS , et al. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Annals of Internal Medicine2011;155(12):839‐47. ">Drekonja 2011</a> published a systematic review of antibiotic therapy for CDI that was limited to RCTs. Eleven studies were included in this review, all of which are also included in the present review and it also was published before the six studies that were added to this update. The outcomes assessed are similar to those presented in the last update of this review. The outcomes assessed in this update have been reduced to symptomatic cure (initial clinical response minus recurrence), bacteriologic cure (initial clearance of <i>C. difficile</i> from the stool, minus recurrence), adverse events related to the intervention, and death. <a href="./references#CD004610-bbs2-0059" title="DiX , BaiN , ZhangX , LiuB , NiW , WangJ , et al. A meta‐analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity. Brazilian Journal of Infectious Diseases2015;19(4):339‐49. [PUBMED: 26001980] ">Di 2015</a> reports a systematic review comparing metronidazole to vancomycin with four RCTs (all included in this review) combined with two cohort studies. The results are largely similar to this review. <a href="./references#CD004610-bbs2-0050" title="BagdasarianN , RaoK , MalaniPN . Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA2015;313(4):398‐408. ">Bagdasarian 2015</a> presents an broadly based review that deals extensively with diagnostic techniques and non‐antibiotic therapy as well as antibiotic treatment. It cites the major published treatment guidelines including those shown in <a href="#CD004610-tbl-0006">Table 2</a> as well as the American College of Gastroenterology guidelines. No reductive meta‐analysis was done for this review. <a href="./references#CD004610-bbs2-0091" title="StewartDB , HollenbeakCS , WilsonMZ . Is colectomy for fulminant Clostridium difficile colitis life saving? A systematic review. Colorectal Disease2013;15(7):798‐804. ">Stewart 2013</a> was a systematic review of surgical mortality in critically ill patients with CDI and as such is the first review of this particular spectrum of CDI, an area where there are no RCTs. Surgery was found to be superior to medical therapy once patients had reached the threshold for severity (OR 0.703, 95% CI 0.497 to 0.994). <a href="./references#CD004610-bbs2-0048" title="Minnesota Evidence‐based Practice Center. Early diagnosis, prevention and treatment of Clostridium difficile: Update. AHRQ Publication No. 16‐EHC012‐EFMarch, 2016; Vol. #172:1‐37. ">AHRQ 2016</a> updated their systematic review and guidelines for diagnosis, prevention and therapy for CDI. This review was not limited to RCTs or antibiotic therapy. </p> <div class="table" id="CD004610-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Published Guidelines for Antibiotic Treatment of CDAD</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HPA<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ESCMID<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SHEA &amp; IDSA<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MILD CDAD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stop inciting antibiotic and observe, or oral metronidazole 500 mg three times daily</p> <p>Alternate dosing also recommended and change to vancomycin if no better in 4 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stop inciting antibiotic and observe, or oral metronidazole 500 mg three times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stop inciting antibiotic, or oral metronidazole 500 mg three times daily for 10 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SEVERE CDAD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral vancomycin 500 mg four times daily with tapering</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral vancomycin 125 mg four times daily for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral vancomycin 125 mg four times daily for 10 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SEVERE AND CANNOT TOLERATE ORAL MEDS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intravenous metronidazole and vancomycin via nasogastric tube or enemas four times daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SURGERY</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For toxic megacolon or lactate &gt; 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For perforation, toxic megacolon, Ileus, lactate &gt; 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RECURRENCE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First as Primary</p> <p>2nd: oral vancomycin with taper</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD004610-bbs2-0069" title="Health Protection Agency of the Department of Health, UK . Clostridium difficile infection: How to deal with the problem. www.gov.uk/government/uploads/system/uploads/attachment_data/file/340851/Clostridium_difficile_infection_how_to_deal_with_the_problem.pdf (accessed 26 January 2017). ">HPA 2008</a>; <a href="./references#CD004610-bbs2-0070" title="Health Protection Agency. Deaths involving Clostridium difficile or MRSA, Wales: 2015. www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsinvolvingclostridiumdifficilewales/2015 (accessed 26 January 2017). ">HPA 2016</a> </p> <p><sup>2</sup><a href="./references#CD004610-bbs2-0055" title="BauerMP , KuijperEJ , vanDisselJT . European society of clinical microbiology and infectious diseases (ESCMID): treatment guidance for Clostridium difficile infection (CDI). Clinical Microbiology and Infection2009;15(12):1067‐79. ">Bauer 2009</a> </p> <p><sup>3</sup><a href="./references#CD004610-bbs2-0058" title="CohenSH , GerdingDN , JohnsonS , KellyCP , LooVG , McDonaldLC , et al. Clinical practice guidelines for clostridium difficile infection in adults: 2010 update for the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology2010;31(5):431‐55. ">Cohen 2010</a> </p> </div> </div> <p>Of interest is one of the excluded studies (<a href="./references#CD004610-bbs2-0031" title="JohnsonS , HomannSR , BettinKM , QuickJN , ClabotsCR , PetersonLR , et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo‐controlled trial. Annals of Internal Medicine1992;117(4):297‐302. ">Johnson 1992</a>). <a href="./references#CD004610-bbs2-0031" title="JohnsonS , HomannSR , BettinKM , QuickJN , ClabotsCR , PetersonLR , et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo‐controlled trial. Annals of Internal Medicine1992;117(4):297‐302. ">Johnson 1992</a> was a randomised, placebo‐controlled, non‐blinded trial of oral vancomycin 125 mg four times a day for 10 days versus oral metronidazole 500 mg two times a day for 10 days versus placebo for the treatment of asymptomatic carriers of C. difficile. This is in fact the only well conducted placebo‐controlled trial related to CDI. <a href="./references#CD004610-bbs2-0009" title="KeighleyMR , BurdonDW , ArabiY , WilliamsJA , ThompsonH , YoungsD , et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. British Medical Journal1978;2(6153):1667‐9. ">Keighley 1978</a>, also a placebo‐controlled trial, suffers from excessive attrition, small size, selection bias and lost specimens. In <a href="./references#CD004610-bbs2-0009" title="KeighleyMR , BurdonDW , ArabiY , WilliamsJA , ThompsonH , YoungsD , et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. British Medical Journal1978;2(6153):1667‐9. ">Keighley 1978</a> asymptomatic <i>C. difficile</i> excretors were identified by rectal swab during infection control surveillance of medical and surgical inpatients at a US Veterans Affairs hospital. Patients were included if they did not have diarrhoea or abdominal symptoms and were not allergic to vancomycin or metronidazole. <i>C. difficile</i> infection was identified by stool culture and cytotoxin assay. The main outcome was presence or absence of <i>C. difficile</i> in the stool during treatment and two months after treatment. A total of 30 patients were equally divided into the three treatment arms. <i>C. difficile</i> organisms were not detected during and immediately after treatment in 9/10 patients treated with vancomycin compared with 3/10 patients treated with metronidazole and 2/10 patients in the placebo group. In contrast, by the end of follow‐up ranging from 40 to over 90 days, <i>C. difficile</i> organisms were not detected in 3/10 patients treated with vancomycin compared with 5/10 patients treated with metronidazole and 8/10 patients in the placebo group. The authors concluded that asymptomatic fecal excretion of <i>C. difficile</i> was transient in most patients and treatment with metronidazole was not effective for eliminating <i>C. difficile</i> from stool. Although treatment with vancomycin was temporarily effective, it was associated with a significantly higher rate of <i>C. difficile</i> carriage two months after treatment and therefore was not recommended for asymptomatic carriers of <i>C. difficile</i> . Although these results were not statistically significant, they are of concern and have stimulated further investigation of strategies to prevent the long‐term carrier state of <i>C. difficile</i>, especially in hospitalised patients (<a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a>; <a href="./references#CD004610-bbs2-0007" title="GareyKW , GhantojiSS , ShahDN , HabibM , AroraV , JiangZD , et al. A randomized, double‐blind, placebo‐controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy2011;66(12):2850‐5. ">Garey 2011</a>; <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a>). </p> <p><a href="./references#CD004610-bbs2-0031" title="JohnsonS , HomannSR , BettinKM , QuickJN , ClabotsCR , PetersonLR , et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo‐controlled trial. Annals of Internal Medicine1992;117(4):297‐302. ">Johnson 1992</a> suggests that the best means of accomplishing the second goal of treatment ‐ elimination of the <i>C. difficile</i> bacterium from the stool of hospitalised patients to prevent spread of infection, is best accomplished with no antibiotic at all. The study by <a href="./references#CD004610-bbs2-0007" title="GareyKW , GhantojiSS , ShahDN , HabibM , AroraV , JiangZD , et al. A randomized, double‐blind, placebo‐controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy2011;66(12):2850‐5. ">Garey 2011</a> would suggest otherwise but like many of the other smaller studies, this study was plagued by a high number of dropouts. While vancomycin has high <i>in vitro</i> activity against <i>C. difficile</i>, it is still not certain that CDI is best treated with this or any other antibiotic (<a href="./references#CD004610-bbs2-0052" title="BartlettJG , TaylorNS , ChangT , DzinkJ . Clinical and laboratory observations in Clostridium difficile colitis. American Journal of Clinical Nutrition1980;33(11 Suppl):2521‐6. ">Bartlett 1980</a>), especially in mild disease. Antibiotic synergy has only been investigated in one study (<a href="./references#CD004610-bbs2-0010" title="LagrottereriaD , HolmesS , SmiejaM , SmaillF , LeeC . Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases2006;43(5):547‐52. ">Lagrotteria 2006</a>), and no clinical benefit was seen by adding rifampin to metronidazole. </p> <p>A propos of this last point, if one does decide to treat CDI, it should be with two goals: improvement of the patient's clinical condition and prevention of spread of <i>C. difficile</i> infection to other patients. Given these two considerations, one should choose the antibiotic that brings both symptomatic cure and bacteriologic cure. In this regard (<a href="./references#CD004610-bbs2-0071" title="JohnsonS , GerdingDN , LouieTJ , RuizNM , GorbachSL . Sustained clinical response as an endpoint in treatment trials of Clostridium difficile‐associated diarrhea. Antimicrobial Agents and Chemotherapy2012;56(8):4043‐5. ">Johnson 2012</a>), teicoplanin might be a good choice, because it was significantly better than vancomycin for bacteriologic cure and has borderline superior effectiveness in terms of symptomatic cure. Teicoplanin is not available in the United States for unknown reasons, which must be taken into account (<a href="./references#CD004610-bbs2-0068" title="JohnsHopkins . Teicoplanin. www.hopkins‐abxguide.org/antibiotics/antibacterial/glycopeptide/teicoplanin.html?contentInstanceId=2548362009. ">Hopkins 2009</a>). Fidaxomicin also presents a new good option, although cost issues have been raised. Now that fidaxomicin has been approved for use in CDI, post marketing surveys should be informative. Most treatment guidelines still recommend metronidazole or no treatment for mild disease and vancomycin for more severe or recurrent illness (<a href="#CD004610-tbl-0006">Table 2</a>). </p> <p><a href="./references#CD004610-bbs2-0019" title="WenischC , ParschalkB , HasenhundlM , HirschlAM , GraningerW . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases1996;22(5):813‐8. ">Wenisch 1996</a> is an important study because it directly compares several antibiotics. This avoids making unrealistic assumptions about relative efficacy made across several randomised trials (<a href="./references#CD004610-bbs2-0051" title="BakerSG , KramerBS . The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C?. BMC Medical Research Methodology2002;2:13. ">Baker 2002</a>). The virulence of C. <i>difficile</i> underlines the need to consider new treatments. Data on four new antibiotics including fidaxomicin, cadazolid, LFF571 and surotomycin are included in this update (<a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a>; <a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a>; <a href="./references#CD004610-bbs2-0014" title="LouieT , NordCE , TalbotGH , WilcoxM , GerdingDN , BuitragoM , et al. Multicenter, double‐blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2015;59(10):6266‐73. ">Louie 2015</a>; <a href="./references#CD004610-bbs2-0015" title="MullaneK , LeeC , BresslerA , BuitragoM , WeissK , DabovicK , et al. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrobial Agents and Chemotherapy2015;59(3):1435‐40. ">Mullane 2015</a>). Several other antibiotics are in development (<a href="./references#CD004610-bbs2-0077" title="LocherHH , CaspersP , BruyereT , SchroederS , PfaffP , KnezevicA , et al. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrobial Agents and Chemotherapy2014;58(2):901‐8. ">Locher 2014</a>; <a href="./references#CD004610-bbs2-0081" title="MieselL , HechtDW , OsmolskiJR , GerdingD , FlatteryA , LiF , et al. Kibdelomycin is a potent and selective agent against toxigenic Clostridium difficile . Antimicrobial Agents and Chemotherapy2014;58(4):2387‐92. ">Miesel 2014</a>; <a href="./references#CD004610-bbs2-0046" title="NCT01983683 . A multi‐center, randomized, double‐blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile‐associated diarrhea (CDAD). clinicaltrials.gov/ct2/show/NCT01983683 (accessed 7 November 2013). ">NCT01983683</a>; <a href="./references#CD004610-bbs2-0047" title="NCT01987895 . A multi‐center, randomized, double‐blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile‐associated diarrhea (CDAD). clinicaltrials.gov/ct2/show/NCT01987895 (accessed 7 November 2013). ">NCT01987895</a>). The concept of toxin binding has been investigated and deserves further attention (<a href="./references#CD004610-bbs2-0035" title="LouieTJ , PeppeJ , WattCK , JohnsonD , MohammedR , DowG , et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases2006;43(4):411‐20. ">Louie 2006</a>). A <i>C. difficile</i> vaccine has also been developed and may provide another alternative to antibiotic treatment (<a href="./references#CD004610-bbs2-0089" title="SougioultzisS , KyneL , DrudyD , KeatesS , MarooS , PothoulakisC , et al. Clostridium difficile toxoid vaccine in recurrent C. difficile‐associated diarrhea. Gastroenterology2005;128(3):764‐70. ">Sougioultzis 2005</a>). Novel therapies, some long forgotten, such as fecal repopulation are reappearing (<a href="./references#CD004610-bbs2-0057" title="BowdenTAJr , MansbergerARJr , LykinsLE . Pseudomembranous enterocolitis: mechanism for restoring floral homeostasis. American Surgeon1981;47(4):178‐83. ">Bowden 1981</a>; <a href="./references#CD004610-bbs2-0074" title="KhorutsA , DicksvedJ , JanssonJK , SadowskyMJ . Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile‐associated diarrhea. Journal of Clinical Gastroenterology2010;44(5):354‐60. ">Khoruts 2010</a>; <a href="./references#CD004610-bbs2-0093" title="VanNoodE , VriezeA , NieuwdorpM , FuentesS , ZoetendalE , DeVosW , et al. Duodenal infusion of donor feces for recurrent Clostridium difficile . New England Journal of Medicine2013;368(5):407‐15. ">Van Nood 2013</a>). </p> <p>The severity scale designed by <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> is important as, for the first time, it attempts to stratify those affected by CDI into mild versus severe disease. Such a scale would be valuable, not only for the standardisation of future studies, but for use in clinical practice, particularly as the study by <a href="./references#CD004610-bbs2-0031" title="JohnsonS , HomannSR , BettinKM , QuickJN , ClabotsCR , PetersonLR , et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo‐controlled trial. Annals of Internal Medicine1992;117(4):297‐302. ">Johnson 1992</a>, for example, suggests that mild disease may be successfully treated without antibiotics (<a href="#CD004610-tbl-0006">Table 2</a>). The severity scale designed by <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> uses any two of the following to indicate severe disease: pyrexia (≥38.3°C), serum albumin of &lt; 2.5 mg/dl, leukocytosis of 15,000 cells/mm<sup>3</sup> and age (≥60 years). There is some discrepancy between subsequent studies as to the appropriate cut‐off points used. For example, <a href="./references#CD004610-bbs2-0012" title="LouieT , MillerM , DonskeyC , MullaneK , GoldsteinEJ . Clinical outcomes, safety and pharmacokinetics of OPT‐80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2009;53(1):223‐8. ">Louie 2009</a> was specifically designed to include patients with mild or moderate disease, and did not exclude patients as 'severe' unless they had a leukocytosis of ≥30,000 cells/mm.<sup>3</sup> The concept of disease severity stratification for specific therapeutic choice has been widely accepted as shown in most guideline publications (<a href="#CD004610-tbl-0006">Table 2</a>). </p> <p>These recommendations should be treated with caution because there is poor evidence supporting recommendations for the treatment of severe disease in <a href="#CD004610-tbl-0006">Table 2</a> due to the exclusion of such patients in the included studies. Patients in all included studies in this review were well enough to be treated with oral antibiotics alone. In addition, the criteria for defining the most severely ill patients in the <a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> study were not at that time clearly associated with prognosis. Most importantly the stratification may have occurred after randomisation and after a number of exclusions, constituting a post hoc subgroup analysis by disease severity. The results of such analyses have been described as best used for exploratory purposes and should not affect trial conclusions (<a href="./references#CD004610-bbs2-0049" title="AssmannSF , PocockSJ , EnosLE , KastenLE . Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet2000;355(9209):1064‐9. ">Assmann 2000</a>). No statistical tests of interaction were performed. Yet five subsequent trials (<a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a>; <a href="./references#CD004610-bbs2-0008" title="JohnsonS , LouieTJ , GerdingDN , CornelyOA , Chasan‐TaberS , FittsD , et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases2014;59(3):345‐54. ">Johnson 2014</a>; <a href="./references#CD004610-bbs2-0012" title="LouieT , MillerM , DonskeyC , MullaneK , GoldsteinEJ . Clinical outcomes, safety and pharmacokinetics of OPT‐80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2009;53(1):223‐8. ">Louie 2009;</a><a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a>; <a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a>), none of which report stratification for severity prior to randomisation, and three recent published guidelines (<a href="./references#CD004610-bbs2-0055" title="BauerMP , KuijperEJ , vanDisselJT . European society of clinical microbiology and infectious diseases (ESCMID): treatment guidance for Clostridium difficile infection (CDI). Clinical Microbiology and Infection2009;15(12):1067‐79. ">Bauer 2009</a>; <a href="./references#CD004610-bbs2-0058" title="CohenSH , GerdingDN , JohnsonS , KellyCP , LooVG , McDonaldLC , et al. Clinical practice guidelines for clostridium difficile infection in adults: 2010 update for the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology2010;31(5):431‐55. ">Cohen 2010</a>; <a href="./references#CD004610-bbs2-0070" title="Health Protection Agency. Deaths involving Clostridium difficile or MRSA, Wales: 2015. www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsinvolvingclostridiumdifficilewales/2015 (accessed 26 January 2017). ">HPA 2016</a>), have adopted this principal of stratification. These guidelines endorse the efficacy of vancomycin for severe disease (<a href="#CD004610-tbl-0006">Table 2</a>). </p> <p>The best means of identifying <i>C. difficile</i> is somewhat controversial (<a href="./references#CD004610-bbs2-0092" title="ThomasC , StevensonM , RileyTV . Antibiotics and hospital‐acquired Clostridium difficile‐associated diarrhoea: a systematic review. Journal of Antimicrobial Chemotherapy2003;51(6):1339‐50. ">Thomas 2003</a>). <a href="./references#CD004610-bbs2-0065" title="GerdingDN , JohnsonS , PetersonLR , MulliganME , SilvaJJr . Clostridium difficile‐associated diarrhea and colitis. Infection Control and Hospital Epidemiology1995;16(8):459‐77. ">Gerding 1995</a> in their position paper for the Society for Healthcare Epidemiology of America recommend either a combination of stool culture for <i>C. difficile</i> and cytotoxin assay or stool cytotoxin testing alone. <a href="./references#CD004610-bbs2-0065" title="GerdingDN , JohnsonS , PetersonLR , MulliganME , SilvaJJr . Clostridium difficile‐associated diarrhea and colitis. Infection Control and Hospital Epidemiology1995;16(8):459‐77. ">Gerding 1995</a> states that most strains of <i>C. difficile</i> produce either both toxin A and toxin B, or neither. Additionally, treatment of patients with diarrhoea who are toxin negative, but culture positive is controversial in that non toxigenic strains of <i>C. difficile</i> are not considered pathogenic (<a href="./references#CD004610-bbs2-0065" title="GerdingDN , JohnsonS , PetersonLR , MulliganME , SilvaJJr . Clostridium difficile‐associated diarrhea and colitis. Infection Control and Hospital Epidemiology1995;16(8):459‐77. ">Gerding 1995</a>). The American College of Gastroenterology practice parameters on the diagnosis and treatment of CDI state that <i>C. difficile</i> can be identified by either positive culture or toxin assay and that if both tests are negative and the diarrhoea persists, then additional stool studies with the same or different tests should be ordered (<a href="./references#CD004610-bbs2-0062" title="FeketyR . Guidelines for the diagnosis and management of Clostridium difficile‐associated diarrhea and colitis. American Journal of Gastroenterology1997;92(5):739‐50. ">Fekety 1997</a>). In light of these two practice guidelines, papers identifying <i>C. difficile</i> by either culture or toxin assay were included in our analysis. The recent CDC paper (<a href="./references#CD004610-bbs2-0076" title="LessaFC , MuY , BambergWM , BeldavsZG , DumyatiGK , DunnJR , et al. Burden of Clostridium difficile infection in the United States. New England Journal of Medicine2015;372(9):825‐34. ">Lessa 2015</a>), a prevalence study in the USA, uses a new stool test, the Nucleic Acid Amplification Test and not symptoms for the diagnosis of CDI. This is a marked change from all the studies included in this review. The current use of polymerase chain reaction (PCR) is still controversial, risking potential over diagnosis and treatment (<a href="./references#CD004610-bbs2-0050" title="BagdasarianN , RaoK , MalaniPN . Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA2015;313(4):398‐408. ">Bagdasarian 2015</a>). </p> <p>The most recent data UK show a more than 50% drop in CDI mortality through 2013, after a rapid rise in mortality up to 2007 (<a href="./references#CD004610-bbs2-0070" title="Health Protection Agency. Deaths involving Clostridium difficile or MRSA, Wales: 2015. www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsinvolvingclostridiumdifficilewales/2015 (accessed 26 January 2017). ">HPA 2016</a>; <a href="./references#CD004610-bbs2-0072" title="KarasJA , EnochDA , AliyuSH . A review of mortality due to Clostridium difficile infection. Journal of Infection2010;61(1):1‐8. ">Karas 2010</a>; <a href="./references#CD004610-bbs2-0085" title="RedelingsMD , SorvilloF , MascolaL . Increase in Clostridium difficile‐related mortality rates, United States, 1999‐2004. Emerging Infectious Diseases2007;13(9):1417‐9. ">Redelings 2007</a>). This may be due to a greater than 50% drop in incidence of CDI in the UK. This may be the result of effective prevention and isolation measures (<a href="./references#CD004610-bbs2-0070" title="Health Protection Agency. Deaths involving Clostridium difficile or MRSA, Wales: 2015. www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsinvolvingclostridiumdifficilewales/2015 (accessed 26 January 2017). ">HPA 2016</a>), and improving awareness of causative antibiotics (<a href="./references#CD004610-bbs2-0084" title="PriviteraG , ScarpelliniP , OrtisiG , NicastroG , NicolinR , deLallaF . Prosepctive study of Clostridium difficile intestinal colonization and disease following single‐dose antibiotic prophylaxis in surgery. Antimicrobial Agents and Chemotherapy1991;35(1):208‐10. ">Privitera 1991</a>; <a href="./references#CD004610-bbs2-0092" title="ThomasC , StevensonM , RileyTV . Antibiotics and hospital‐acquired Clostridium difficile‐associated diarrhoea: a systematic review. Journal of Antimicrobial Chemotherapy2003;51(6):1339‐50. ">Thomas 2003</a>; <a href="./references#CD004610-bbs2-0082" title="NovellMJ , MorrealeCA . The relationship between inpatient fluoroquinolone use and Clostridium difficile‐associated diarrhea. Annals of Pharmacotherapy2010;44(5):826‐31. ">Novell 2010</a>). This is a marked difference from the recently presented prevalence data from the CDC in the USA, in which no decline is documented in the USA, rather a continuing rise (<a href="./references#CD004610-bbs2-0076" title="LessaFC , MuY , BambergWM , BeldavsZG , DumyatiGK , DunnJR , et al. Burden of Clostridium difficile infection in the United States. New England Journal of Medicine2015;372(9):825‐34. ">Lessa 2015</a>). This may in part be due to the increased sensitivity of newer diagnostic test for CDI. </p> <p>Cost was investigated in this update. Previous versions of this review had data that are now far out of date. In short, the cost of teicoplanin has decreased (but not vancomycin) and for now at least the cost of a course of fidaxomicin is in excess of USD 3400. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004610-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/urn:x-wiley:14651858:media:CD004610:CD004610-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_t/tCD004610-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD004610-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/full#CD004610-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004610-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/urn:x-wiley:14651858:media:CD004610:CD004610-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_t/tCD004610-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD004610-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/full#CD004610-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004610-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/urn:x-wiley:14651858:media:CD004610:CD004610-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_t/tCD004610-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD004610-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/full#CD004610-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004610-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/urn:x-wiley:14651858:media:CD004610:CD004610-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_t/tCD004610-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metronidazole vs Vancomycin, Outcome 1 Sustained Symptomatic Cure with all exclusions treated as failures." data-id="CD004610-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Metronidazole vs Vancomycin, Outcome 1 Sustained Symptomatic Cure with all exclusions treated as failures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/references#CD004610-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004610-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/urn:x-wiley:14651858:media:CD004610:CD004610-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_t/tCD004610-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metronidazole vs Vancomycin, Outcome 2 Bacteriologic Cure." data-id="CD004610-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Metronidazole vs Vancomycin, Outcome 2 Bacteriologic Cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/references#CD004610-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004610-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/urn:x-wiley:14651858:media:CD004610:CD004610-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_t/tCD004610-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metronidazole vs Vancomycin, Outcome 3 Sustained Cure (Combined symptomatic and bacteriologic cure)." data-id="CD004610-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Metronidazole vs Vancomycin, Outcome 3 Sustained Cure (Combined symptomatic and bacteriologic cure). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/references#CD004610-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004610-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/urn:x-wiley:14651858:media:CD004610:CD004610-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_t/tCD004610-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bacitracin vs Vancomycin, Outcome 1 Symptomatic Cure." data-id="CD004610-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Bacitracin vs Vancomycin, Outcome 1 Symptomatic Cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/references#CD004610-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004610-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/urn:x-wiley:14651858:media:CD004610:CD004610-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_t/tCD004610-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Teicoplanin vs Vancomycin, Outcome 1 Symptomatic Cure." data-id="CD004610-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Teicoplanin vs Vancomycin, Outcome 1 Symptomatic Cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/references#CD004610-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004610-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/urn:x-wiley:14651858:media:CD004610:CD004610-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_t/tCD004610-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Teicoplanin vs Vancomycin, Outcome 2 Bacteriologic Cure." data-id="CD004610-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Teicoplanin vs Vancomycin, Outcome 2 Bacteriologic Cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/references#CD004610-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004610-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/urn:x-wiley:14651858:media:CD004610:CD004610-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_t/tCD004610-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Metronidazole vs Fusidic Acid, Outcome 1 Symptomiatic Cure." data-id="CD004610-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Metronidazole vs Fusidic Acid, Outcome 1 Symptomiatic Cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/references#CD004610-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004610-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/urn:x-wiley:14651858:media:CD004610:CD004610-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_t/tCD004610-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Metronidazole vs Fusidic Acid, Outcome 2 Bacteriologic Cure." data-id="CD004610-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Metronidazole vs Fusidic Acid, Outcome 2 Bacteriologic Cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/references#CD004610-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004610-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/urn:x-wiley:14651858:media:CD004610:CD004610-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_t/tCD004610-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Fidaxomicin vs Vancomycin, Outcome 1 Symptomatic Cure." data-id="CD004610-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Fidaxomicin vs Vancomycin, Outcome 1 Symptomatic Cure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/references#CD004610-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/media/CDSR/CD004610/image_n/nCD004610-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004610-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Metronidazole versus vancomycin for Clostridium difficile‐associated diarrhoea in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Metronidazole versus Vancomycin for Clostridium difficile‐associated diarrhoea in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Clostridium difficile‐associated diarrhoea in adults<br/> <b>Settings:</b> <br/> <b>Intervention:</b> Metronidazole versus Vancomycin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Metronidazole versus Vancomycin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic cure with all exclusions treated as failures</b> <br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>792 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>713 per 1000</b> <br/> (665 to 768) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.9</b> <br/> (0.84 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>872<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bacteriologic cure</b> <br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>529 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>449 per 1000</b> <br/> (328 to 619) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b> <br/> (0.62 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cure (combined symptomatic and bacteriologic cure) ‐ mild disease</b> <br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>841 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>740 per 1000</b> <br/> (597 to 917) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> <br/> (0.71 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cure (combined symptomatic and bacteriologic cure) ‐ severe disease</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>711 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>526 per 1000</b> <br/> (369 to 739) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.74</b> <br/> (0.52 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk comes from control arm of meta‐analysis, based on included trials.<br/> <sup>2</sup> High risk of bias.<br/> <sup>3</sup> Serious imprecision.<br/> <sup>4</sup> Unclear risk of bias.<br/> <sup>5</sup> Unclear if stratification by severity was post hoc. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Metronidazole versus vancomycin for Clostridium difficile‐associated diarrhoea in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/full#CD004610-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004610-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Teicoplanin versus vancomycin for Clostridium difficile‐associated diarrhoea in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Teicoplanin versus Vancomycin for Clostridium difficile‐associated diarrhoea in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Clostridium difficile‐associated diarrhoea in adults<br/> <b>Settings:</b> <br/> <b>Intervention:</b> Teicoplanin versus Vancomycin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Teicoplanin versus Vancomycin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic Cure</b> <br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>727 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>880 per 1000</b> <br/> (727 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.21</b> <br/> (1 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bacteriologic Cure</b> <br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>452 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>822 per 1000</b> <br/> (537 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.82</b> <br/> (1.19 to 2.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk comes from control arm of meta‐analysis, based on included trials. <br/> <sup>2</sup> High risk of bias. Blinding not done in either study and other pathogens not excluded in Wenisch<br/> <sup>3</sup> Serious imprecision. Two very small studies<br/> <sup>4</sup> Serious imprecision. Just a single small study </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Teicoplanin versus vancomycin for Clostridium difficile‐associated diarrhoea in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/full#CD004610-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004610-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Fidaxomicin compared to vancomycin for Clostridium difficile‐associated diarrhoea in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fidaxomicin compared to Vancomycin for Clostridium difficile‐associated diarrhoea in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Clostridium difficile‐associated diarrhoea in adults<br/> <b>Settings:</b> <br/> <b>Intervention:</b> Fidaxomicin<br/> <b>Comparison:</b> Vancomycin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Vancomycin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Fidaxomicin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic Cure</b> <br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>610 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>713 per 1000</b> <br/> (652 to 774) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.17</b> <br/> (1.07 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1164<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk comes from control arm of meta‐analysis, based on included trials.<br/> <sup>2</sup> High risk of bias in both studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Fidaxomicin compared to vancomycin for Clostridium difficile‐associated diarrhoea in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/full#CD004610-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004610-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Bacitracin versus vancomycin for Clostridium difficile‐associated diarrhoea in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bacitracin versus Vancomycin for Clostridium difficile‐associated diarrhoea in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Clostridium difficile‐associated diarrhoea in adults<br/> <b>Settings:</b> <br/> <b>Intervention:</b> Bacitracin versus Vancomycin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Bacitracin versus Vancomycin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic Cure</b> <br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>462 per 1000</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>268 per 1000</b> <br/> (157 to 457) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.58</b> <br/> (0.34 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk comes from control arm of meta‐analysis, based on included trials.<br/> <sup>2</sup> High risk of bias. Attrition and blinding issues in one trial.<br/> <sup>2</sup> Very serious imprecision. Two very small studies with few events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Bacitracin versus vancomycin for Clostridium difficile‐associated diarrhoea in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/full#CD004610-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004610-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n=Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Deaths</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Harms due to</b> </p> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Attrition%</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Stratified by</b> </p> <p><b>Severity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0001" title="Anonymous . Treatment of Clostridium difficile‐associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group. Scandinavian Journal of Infectious Diseases1994;26(3):309‐16. ">Anonymous 1994</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>joint pain</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;10%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0002" title="BoeroM , BertiE , MorgandoA , VermeG . Treatment of pseudomembranous colitis: a randomized controlled trial with rifaximin vs vancomycin [Terapia della colite da Clostridium difficile: risultati di uno studio randomizzato aperto rifaximina vs. vancomicina]. Microbiologia Medica1990;5(2):74‐7. ">Boero 1990</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0003" title="CornelyOA , CrookDW , EspositoR , PoirierA , SomeroMS , WeissK , et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double‐blind, non‐inferiority, randomised controlled trial. Lancet Infectious Diseases2012;12(4):281‐9. ">Cornley 2012</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>535</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 Fid</p> <p>17 Van</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>none</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.9%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes post</p> <p>randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0004" title="DeLallaF , NicolinR , RinaldiE , ScarpelliniP , RigoliR , ManfrinV , et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile‐associated diarrhea. Antimicrobial Agents and Chemotherapy1992;36(10):2192‐6. ">De Lalla 1992</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0005" title="DudleyMN , McLaughlinJC , CarringtonG , FrickJ , NightingaleCH , QuintilianiR . Oral bacitracin vs vancomycin therapy for Clostridium difficile‐induced diarrhea. A randomized double‐blind trial. Archives of Internal Medicine1986;146(6):1101‐4. ">Dudley 1986</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0006" title="FeketyR , SilvaJ , KauffmanC , BuggyB , DeeryHG . Treatment of antibiotic‐associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. American Journal of Medicine1989;86(1):15‐9. ">Fekety 1989</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0007" title="GareyKW , GhantojiSS , ShahDN , HabibM , AroraV , JiangZD , et al. A randomized, double‐blind, placebo‐controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy2011;66(12):2850‐5. ">Garey 2011</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>skin rash</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0008" title="JohnsonS , LouieTJ , GerdingDN , CornelyOA , Chasan‐TaberS , FittsD , et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases2014;59(3):345‐54. ">Johnson 2014</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1118</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 Met</p> <p>16 Van</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>none</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes post</p> <p>randonisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0010" title="LagrottereriaD , HolmesS , SmiejaM , SmaillF , LeeC . Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases2006;43(5):547‐52. ">Lagrotteria 2006</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0011" title="LeeCH , PatinoH , StevensC , RegeS , ChesnelL , LouieT , et al. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double‐blind, non‐inferiority, multicentre trial. Journal of Antimicrobial Chemotherapy2016;71(10):2964‐71. ">Lee 2016a</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>209</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0012" title="LouieT , MillerM , DonskeyC , MullaneK , GoldsteinEJ . Clinical outcomes, safety and pharmacokinetics of OPT‐80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2009;53(1):223‐8. ">Louie 2009</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0013" title="LouieTJ , MillerMA , MullaneKM , WeissK , LentnekA , GolanY , et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine2011;364(5):422‐31. ">Louie 2011</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>629</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 Fid</p> <p>21 Van</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>elevated</p> <p>liver enzymes</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.2%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes post</p> <p>randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0014" title="LouieT , NordCE , TalbotGH , WilcoxM , GerdingDN , BuitragoM , et al. Multicenter, double‐blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrobial Agents and Chemotherapy2015;59(10):6266‐73. ">Louie 2015</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0015" title="MullaneK , LeeC , BresslerA , BuitragoM , WeissK , DabovicK , et al. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrobial Agents and Chemotherapy2015;59(3):1435‐40. ">Mullane 2015</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0016" title="MusherDM , LoganN , HamillRJ , DupontHL , LentnekA , GuptaA , et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clinical Infectious Diseases2006;43(4):421‐7. ">Musher 2006</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0017" title="MusherDM , LoganN , BresslerAM , JohnsonDP , RossignolJF . Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double‐blind study. Clinical Infectious Diseases2009;48(4):41‐6. ">Musher 2009</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes post</p> <p> randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0018" title="TeasleyDG , GerdingDN , OlsonMM , PetersonLR , GebhardRL , SchwartzMJ , et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile‐associated diarrhoea and colitis. Lancet1983;2(8358):1043‐6. ">Teasley 1983</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0019" title="WenischC , ParschalkB , HasenhundlM , HirschlAM , GraningerW . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clinical Infectious Diseases1996;22(5):813‐8. ">Wenisch 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>126</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0020" title="WulltM , OdenholtI . A double‐blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile‐associated diarrhoea. Journal of Antimicrobial Chemotherapy2004;54(1):211‐6. ">Wullt 2004</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0021" title="YoungGP , WardPB , BayleyN , GordonD , HigginsG , TrapaniJA , et al. Antibiotic‐associated colitis due to Clostridium difficile: double‐blind comparison of vancomycin with bacitracin. Gastroenterology1985;89(5):1038‐45. ">Young 1985</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004610-bbs2-0022" title="ZarFA , BakkanagariSR , MoorthiKM , DavisMB . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clinical Infectious Diseases2007;45(3):302‐7. ">Zar 2007</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>172</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13%</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes but</p> <p>uncertain</p> <p>when</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TOTAL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>NR: None reported</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/full#CD004610-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004610-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Published Guidelines for Antibiotic Treatment of CDAD</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HPA<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ESCMID<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SHEA &amp; IDSA<sup>3</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MILD CDAD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stop inciting antibiotic and observe, or oral metronidazole 500 mg three times daily</p> <p>Alternate dosing also recommended and change to vancomycin if no better in 4 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stop inciting antibiotic and observe, or oral metronidazole 500 mg three times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stop inciting antibiotic, or oral metronidazole 500 mg three times daily for 10 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SEVERE CDAD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral vancomycin 500 mg four times daily with tapering</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral vancomycin 125 mg four times daily for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral vancomycin 125 mg four times daily for 10 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SEVERE AND CANNOT TOLERATE ORAL MEDS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intravenous metronidazole and vancomycin via nasogastric tube or enemas four times daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SURGERY</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For toxic megacolon or lactate &gt; 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For perforation, toxic megacolon, Ileus, lactate &gt; 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RECURRENCE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First as Primary</p> <p>2nd: oral vancomycin with taper</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD004610-bbs2-0069" title="Health Protection Agency of the Department of Health, UK . Clostridium difficile infection: How to deal with the problem. www.gov.uk/government/uploads/system/uploads/attachment_data/file/340851/Clostridium_difficile_infection_how_to_deal_with_the_problem.pdf (accessed 26 January 2017). ">HPA 2008</a>; <a href="./references#CD004610-bbs2-0070" title="Health Protection Agency. Deaths involving Clostridium difficile or MRSA, Wales: 2015. www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsinvolvingclostridiumdifficilewales/2015 (accessed 26 January 2017). ">HPA 2016</a> </p> <p><sup>2</sup><a href="./references#CD004610-bbs2-0055" title="BauerMP , KuijperEJ , vanDisselJT . European society of clinical microbiology and infectious diseases (ESCMID): treatment guidance for Clostridium difficile infection (CDI). Clinical Microbiology and Infection2009;15(12):1067‐79. ">Bauer 2009</a> </p> <p><sup>3</sup><a href="./references#CD004610-bbs2-0058" title="CohenSH , GerdingDN , JohnsonS , KellyCP , LooVG , McDonaldLC , et al. Clinical practice guidelines for clostridium difficile infection in adults: 2010 update for the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology2010;31(5):431‐55. ">Cohen 2010</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Published Guidelines for Antibiotic Treatment of CDAD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/full#CD004610-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004610-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Metronidazole vs Vancomycin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Sustained Symptomatic Cure with all exclusions treated as failures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.84, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Bacteriologic Cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.62, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Sustained Cure (Combined symptomatic and bacteriologic cure) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.68, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Mild disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.71, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Severe disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.52, 1.04]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Metronidazole vs Vancomycin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/references#CD004610-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004610-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Bacitracin vs Vancomycin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Symptomatic Cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.34, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Bacitracin vs Vancomycin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/references#CD004610-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004610-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Teicoplanin vs Vancomycin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Symptomatic Cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.00, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Bacteriologic Cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.19, 2.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Teicoplanin vs Vancomycin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/references#CD004610-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004610-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Metronidazole vs Fusidic Acid</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Symptomiatic Cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.88, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Bacteriologic Cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.84, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Metronidazole vs Fusidic Acid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/references#CD004610-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004610-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Fidaxomicin vs Vancomycin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Symptomatic Cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [1.07, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Fidaxomicin vs Vancomycin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004610.pub5/references#CD004610-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004610.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004610-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004610-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004610-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD004610-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD004610-note-0004">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD004610-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD004610-note-0001">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD004610-note-0002">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004610\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004610\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004610\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004610\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004610\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004610\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004610\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004610\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004610\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004610\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004610\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004610\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004610\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004610\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004610\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004610\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004610\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004610\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=na56WA6j&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004610.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004610.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004610.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004610.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004610.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724273011"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004610.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724273014"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004610.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e5ecb6b5ff409',t:'MTc0MDcyNDI3My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 